Anti-sars-cov-2 spike protein antibodies

Abstract

The present disclosure provides antibodies or antigen-binding fragments thereof that specifically recognize SARS-CoV-2 S protein. The antibodies or antigen-binding fragments thereof described in the present disclosure can be formulated into pharmaceutical compositions and / or used for various diagnostic, therapeutic, or molecular biology applications.

Description

[0001] Cross-reference to related applications

[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 015,037, filed April 24, 2020, the entire contents of which are incorporated herein by reference.

[0003] Merge into the sequence list

[0004] This patent application contains a sequence list, which is filed electronically with this application, the entire contents of which are incorporated herein by reference. An ASCII copy was created on April 23, 2021, named SCT0013-401-PC_Sequence_List_ST25.txt, and is 485,209 bytes in size. Background Technology

[0005] SARS-CoV-2 enters host cells via a dense array of glycosylated spike (S) proteins. The following are findings about SARS-CoV, but many of these findings are also relevant to SARS-CoV-2 due to their close association at the DNA sequence level. The S protein is a trimeric class I fusion protein that exists in a metastable pre-fusion conformation, undergoing significant structural rearrangement to fuse the viral membrane with the host cell membrane (Li, 2016; Bosch et al., 2003). This process is triggered when the S1 subunit binds to the host cell receptor. Receptor binding destabilizes the pre-fusion trimer structure, leading to the shedding of the S1 subunit and the transformation of the S2 subunit into a stable post-fusion conformation (Walls et al., 2017). To bind to the host cell receptor, the receptor-binding domain (RBD) of S1 undergoes hinge-like conformational movement, temporarily concealing or exposing the receptor-binding determinant cluster. The S2 domain of the S protein mediates the fusion of the virus and the host membrane through conformational changes, causing the two conserved helical regions of the S protein (HR1 and HR2) to combine to form a six-helix bundle fusion core, thereby leading to the infection of target cells (He et al., 2005a).

[0006] The S protein is a major antigen that elicits a protective immune response, including neutralizing antibodies produced in infected humans and animals (Bisht et al., 2004; Buchholz et al., 2004; Cheng et al., 2005).

[0007] Greenough et al., 2005; He et al., 2005b; Hofmann et al., 2004. Immunization of mice with DNA vaccines encoding the S sequence (lacking cytoplasmic and / or transmembrane domains) elicited neutralizing antibodies and CD4+ and CD8+ T cell responses (Yang et al., 2004). However, it was not cellular immunity that suppressed viral replication, but rather humoral (IgG) component immunity (Yang et al., 2004). In fact, convalescent plasma therapy in China has achieved considerable success (Duan et al., 2020). In summary, these studies indicate that SARS-CoV replication is primarily suppressed by antibodies, and that passively transferred anti-SARS-CoV neutralizing antibodies have potential therapeutic value. The immunogenicity of the S protein, including its ability to induce neutralizing antibody production and its important role in viral attachment and fusion, makes it an ideal target for developing effective immunotherapies to prevent SARS-CoV-2 infection.

[0008] In fact, sequence analysis has shown that clinical isolates can be classified into early, intermediate, and late-stage isolates (Sui et al., 2005). This allows subsequent isolates to evade neutralization by relying on monoclonal antibodies that can effectively neutralize early isolates (Yang et al., 2005). Therefore, it is crucial to produce neutralizing monoclonal antibodies (mAbs) effective against a wide range of clinical isolates with antigenic diversity. Given the potential for antigenic variant evolution, effective passive therapies against SARS-CoV-2 will likely involve mixtures of neutralizing antibodies targeting different epitopes and / or steps in the invasion process, such as blocking receptor binding and fusion or Fc signaling.

[0009] Passive therapy with appropriate humanized antiviral immunoglobulins (such as those disclosed in this invention) can provide immediate protection. Therefore, there remains an urgent need for effective broad-spectrum antibody therapies for the treatment of SARS-CoV-2 infection. Summary of the Invention

[0010] The antibodies provided in this disclosure can recognize and specifically bind to the SARS-CoV-2S protein. In one embodiment, this disclosure provides an antibody that binds to SEQ ID NO:1.

[0011] Sequence Description

[0012] Table 1

[0013]

[0014]

[0015]

[0016]

[0017]

[0018]

[0019]

[0020]

[0021]

[0022]

[0023]

[0024]

[0025]

[0026] Attached Figure Description

[0027] Figure 1 The image shows a binary map of epitope regions from the selected anti-SARS-CoV-2 antibody subgroups. Antibodies within the circles either share the same epitope or have largely overlapping epitopes. Overlapping circles indicate the limitations of the BLI assay in accurately delineating the boundaries of these regions.

[0028] Overlapping segments may indicate a low degree of epitope overlap. For example, SCT-La190 and SCT-La115 are not in separate segments, while SCT-La102 is definitely in a separate segment.

[0029] Figure 2 The figure shows the titration plot of the selected antibody subgroups, illustrating their ability to inhibit reporter virus particles (RVP) infection of appropriate host cells. The data points indicate that antibodies exhibiting significant inhibitory levels at lower concentrations have higher potency. The IC50 value for each antibody can be reasonably calculated based on the data points shown. Detailed Implementation

[0030] This disclosure provides antibodies that bind to the SARS-CoV-2S protein. In one embodiment, this disclosure provides an isolated antibody that binds to SEQ ID NO:1.

[0031] Antibody

[0032] This disclosure provides an antibody that specifically binds to SEQ ID NO:1. As used herein, the term "antibody" includes full-length immunoglobulins as well as antibody fragments that bind to BCMA. Such antibodies can be monoclonal antibodies, polyclonal antibodies, chimeric antibodies, humanized antibodies, or single-chain antibodies, etc. As used herein, the terms "antigen-binding fragment," "fraction," and "antibody fragment" are used interchangeably and refer to any fragment comprising a portion of a full-length antibody, typically at least the antigen-binding portion or its variable region. Examples of antibody fragments include, but are not limited to, nanobodies, biantibodies, bispecific T-cell conjugates, single-chain antibody molecules, multispecific antibodies (e.g., bispecific), Fab, Fab', F(ab')2, Fv, or scFv.

[0033] Compositions containing all the antibody-antigen binding fragments described herein were considered.

[0034] As used in this article, the term “excipient” refers to a natural or synthetic substance formulated together with the active pharmaceutical ingredient, including for the purpose of long-term stability, filling solid dosage forms, or to impart therapeutic enhancement to the active ingredient in the final dosage form, such as promoting drug absorption, reducing viscosity, or enhancing solubility.

[0035] The phrase “therapeuticly effective” is intended to define the amount of active ingredient used to treat a disease or condition or to influence clinical endpoints.

[0036] The term “therapeutically acceptable” refers to compounds (or salts, prodrugs, tautomers, zwitterionic forms, etc.) that are suitable for contact with patient tissues without excessive toxicity, irritation, or allergic reactions, have a reasonable benefit / risk ratio, and are effective for their intended use.

[0037] As used in this article, the term "treatment" refers to improving a disease, thereby reducing, improving, or eliminating its cause, progression, severity, or one or more symptoms, or beneficially altering the disease in a subject. The term "treatment" for a patient is intended to include prevention. Treatment can also be prophylactic in nature, meaning it may include helping subjects exposed to or at risk of developing the disease to prevent it. Disease prevention may involve completely preventing the disease, such as in the case of preventing infection by a pathogen, or it may involve preventing the progression of the disease. For example, disease prevention may not mean completely eliminating any disease-related effects at any level, but may mean controlling disease symptoms to a clinically significant or detectable level. Disease prevention can also refer to preventing the disease from progressing to a later stage.

[0038] The terms “subject” and “patient” are used interchangeably in this document and refer to all mammals, including humans. Examples of subjects include, but are not limited to, humans, monkeys, dogs, cats, horses, cows, goats, sheep, pigs, and rabbits. In one embodiment, the subject or patient is a human.

[0039] As used in this article, “moderate COVID-19” refers to an individual who, upon clinical assessment or imaging, shows signs of lower respiratory tract disease and has an oxygen saturation (SpO2) ≥94% in indoor air at sea level. While a diagnosis can be made based on clinical evidence, chest imaging (X-ray, CT scan, ultrasound) may be helpful in diagnosing and identifying or ruling out pulmonary complications.

[0040] As used in this article, “standard of care” or “SOC” refers to the diagnostic and treatment procedures that clinicians should follow for a specific type of patient, disease, or clinical situation. SOC may include administering medications used in clinical practice to treat COVID-19 (e.g., lopinavir / ritonavir; darunavir / cobicistat; hydroxychloroquine, tuximab, etc.), but may exclude medications used in another clinical trial.

[0041] As used in this article, "acute respiratory distress syndrome" or "ARDS" is a type of respiratory failure characterized by a rapid onset of widespread inflammation in the lungs. Symptoms include shortness of breath, rapid breathing, and cyanosis.

[0042] In some embodiments, the antibodies provided in this disclosure can be used to identify patients infected with SARS-CoV-2 by specifically detecting the virus through its S protein.

[0043] This testing is essential to protect frontline healthcare workers, allowing them to isolate infected individuals and treat them before their condition worsens. Epidemiologists can reliably identify infected individuals in high-incidence areas to better gauge the extent of the outbreak, and government officials can use these results to help determine when and how to resume daily life for residents. Most importantly, it is crucial for economic recovery, as identifying and isolating infected individuals allows the rest of society to function normally.

[0044] In one aspect, this disclosure provides a composition or kit comprising an antibody or antigen-binding fragment as described above or herein and used in combination with another therapeutic agent.

[0045] In one aspect, the present invention provides a pharmaceutical composition comprising an antigen-binding protein, an antibody or antigen-binding fragment as described above or herein, and a pharmaceutically acceptable carrier, and optionally another therapeutic agent. In some embodiments, the other therapeutic agent is an antiviral drug or a vaccine. In some embodiments, the other therapeutic agent is selected from a combination of anti-inflammatory and antimalarial agents. In some cases, the antimalarial agent is chloroquine or hydroxychloroquine. In some cases, the anti-inflammatory agent is an antibody, such as salperamide, tocilizumab, or ginsulbuvir. In some embodiments, the other therapeutic agent is a second antibody or antigen-binding fragment comprising the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of Table 3.

[0046] In one aspect, this disclosure provides a pharmaceutical composition comprising an isolating antibody or an antigen-binding fragment thereof as described above or herein, and a pharmaceutically acceptable carrier or diluent. In some embodiments, the pharmaceutical composition comprises one or more excipients.

[0047] In some embodiments, the pharmaceutical composition further comprises a second therapeutic agent. In some cases, the second therapeutic agent is selected from combinations of the following drugs: a second antibody or its antigen-binding fragment (binding to the SARS-CoV-2 spike protein comprising the amino acid sequence described in SEQ ID NO:1), an anti-inflammatory agent, and an antimalarial agent.

[0048] This disclosure provides an antibody that specifically binds to SEQ ID NO:1. As used herein, the term "antibody" includes full-length immunoglobulins and antibody fragments that bind to the same antigen. Such antibodies can be monoclonal antibodies, polyclonal antibodies, chimeric antibodies, humanized antibodies, or single-chain antibodies, etc.

[0049] The antibodies provided can be used to diagnose, treat, or monitor SARS-CoV-2 virus infection.

[0050] In some embodiments, the antibodies or fragments thereof described herein may be used for a variety of in vitro molecular biology applications, such as enzyme-linked immunosorbent assay (ELISA), Western blotting, immunohistochemistry, immunocytochemistry, flow cytometry and fluorescence-activated cell sorting (FACS), immunoprecipitation and / or enzyme-linked immunospot assays. In some embodiments, the antibodies or fragments thereof may be packaged in a kit with or without additional reagents known to those skilled in the art for performing any of the molecular biology techniques described above.

[0051] On the other hand, this disclosure provides a method for preventing or treating SARS-CoV-2 infection in a subject in need, comprising administering to the subject a therapeutically or prophylactically effective amount of a pharmaceutical composition comprising one or more antibodies described herein. This method may include administering, at any dose, an antibody described herein that effectively improves or treats symptoms of SARS-CoV-2 infection.

[0052] In some embodiments, a pharmaceutical composition comprising one or more antibodies described herein may be administered to a subject exposed to SARS-CoV-2. In some embodiments, the pharmaceutical composition described herein may be administered alone or in combination with other therapies deemed appropriate by a clinician or practitioner. In some embodiments, the pharmaceutical composition described herein may reduce the number of days of COVID-19 symptoms by one or more days, for example, by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days.

[0053] In another aspect, this disclosure provides methods for reducing, delaying or otherwise inhibiting the growth and / or replication of SARS-CoV-2 in individuals diagnosed with COVID-19, including administering a pharmaceutical composition comprising one or more antibodies described herein.

[0054] In some embodiments, the severity of COVID-19 is moderate. In some embodiments, administration of a prophylactic or therapeutic dose of one or more antibodies described herein begins within 24 to 72 hours of the onset of illness or when an individual is diagnosed with COVID-19, whichever is earlier. In some embodiments, administration begins within 24 hours of the onset of illness or when an individual is diagnosed with COVID-19, whichever is earlier.

[0055] In some embodiments, an individual is at high risk of exposure to SARS-CoV-2. In some embodiments, the individual is a healthcare worker. In some embodiments, the individual is located in an area where SARS-CoV-2 has been reported to be spreading in the community. In some embodiments, the individual has had close contact with one or more COVID-19 patients.

[0056] In some embodiments, the individual is at higher risk of developing a serious illness. In some embodiments, the individual is 60 years of age or older. In some embodiments, the individual has a serious chronic illness. In some embodiments, the chronic illness is selected from lung disease, type 2 diabetes, requiring oral medication or insulin therapy, hypertension, and cardiovascular disease.

[0057] In some embodiments, the individual's baseline systolic blood pressure at rest is less than 110 mmHg. In some embodiments, the individual's body mass index is ≥30.

[0058] In some embodiments, the method further includes detecting SARS-CoV-2 infection in an individual. In some embodiments, the test includes detection of nasopharyngeal and oropharyngeal swabs by real-time reverse transcription-polymerase chain reaction (rRT-PCR). A description of this assay and sequence information for the rRT-PCR primers and probes are available on the CDC Laboratory Information website for 2019-nCoV (https: / / www.cdc.gov / coronavirus / 2019-nCoV / lab / index.html), the entire contents of which are incorporated herein by reference.

[0059] The present disclosure provides antibodies SCT-La001, SCT-La002, SCT-La003, SCT-La004, SCT-La005, SCT-La006, SCT-La007, SCT-La008, SCT-La009, SCT-La010, SCT-La011, SCT-La012, SCT-La013, SCT-La014, SCT-La015, SCT-La016, SCT-La017, SCT-La018, SCT-La019, SCT-La020, SCT-La021, SCT-La022, SCT-La023, SCT-La024, SCT-La025, SCT-La026, SCT-La027, SCT-La028, SCT-La029, SCT-La030, SCT-La031, SCT-La032, SCT-La033, SCT-La034, SCT-La035, SCT-La036, SCT-La037, SCT-La038, SCT-La039, SCT-La040, SCT-La041, SCT-La042, SCT-La043, SCT-La044, SCT-La045, SCT-La046, SCT-La047, SCT-La048, SCT-La049, SCT-La050, SCT-La051, SCT-La052, SCT-La053, SCT-La054, SCT-La055, SCT-La056, SCT-La057, SCT-La058, SCT-La059, SCT-La060, SCT-La061, SCT-La062, SCT-La063, SCT-La064, SCT-La065, SCT-La066, SCT-La067, SCT-La068, SCT-La069, SCT-La070, SCT-La071, SCT-La072, SCT-La073, SCT-La074, SCT-La075, SCT-La076, SCT-La077, SCT-La078, SCT-La079, SCT-La080, SCT-La081, SCT-La082, SCT-La083, SCT-La084, SCT-La(085, SCT-La086, SCT-La087, SCT-La088, SCT-La089, SCT-La090, SCT-La091, SCT-La092, SCT-La093, SCT-La094, SCT-La095, SCT-La096, SCT-La097, SCT-La098, SCT-La099,SCT-La100,SCT-La101,SCT-La102,SCT-La103,SCT-La104,SCT-La105,SCT-La106,SCT-La107,SCT-La108,SCT-La109,SCT-La110,SCT-La111,SCT-La112,SCT-La113,SCT-La114,SCT-La115,SCT-La116,SCT-La117,SCT-La118,SCT-La119,SCT-La120,SCT-La121,SCT-La122,SCT-La123,SCT-La124, SCT-La125,SCT-La126,SCT-La127,SCT-La128,SCT-La129,SCT-La130,SCT-La131,SCT-La132,SCT-La133,SCT-La134,SCT-La135,SCT-La136,SCT-La137,SCT-La138,SCT-La139,SCT-La140,SCT-La141,SCT-La142,SCT-La143,SCT-La144,SCT-La145,SCT-La146,SCT-La147,SCT-La148,SCT-La149, SCT-La150,SCT-La151,SCT-La152,SCT-La153,SCT-La154,SCT-La155,SCT-La156,SCT-La157,SCT-La158,SCT-La159,SCT-La160,SCT-La161,SCT-La162,SCT-La163,SCT-La164,SCT-La165,SCT-La166,SCT-La167,SCT-La168,SCT-La169,SCT-La170,SCT-La171,SCT-La172,SCT-La173,SCT-La174, SCT-La175,SCT-La176,SCT-La177,SCT-La178,SCT-La179,SCT-La180,SCT-La181,SCT-La182,SCT-La183,SCT-La184,SCT-La185,SCT-La186,SCT-L a187,SCT-La188,SCT-La189,SCT-La190,SCT-La191,SCT-La192,SCT-La193,SCT-La194,SCT-La195,SCT-La196,SCT-La197,SCT-La198,SCT-La199,SCT-La200, SCT-La201, SCT-La202, SCT-La203, SCT-La204, SCT-La205, SCT-La206, SCT-La207, SCT-La208, SCT-La209, SCT-La210, SCT-La211, SCT-La212, SCT-La213, SCT-La214, SCT-La215, SCT-La216, SCT-La217, SCT-La218, SCT-La219, SCT-La220, SCT-La221, SCT-La222, SCT-La223, SCT-La224, and SCT-La225. Each of these is a mouse monoclonal antibody.

[0060] Furthermore, recombinant anti-SARS-CoV-2S protein antibodies, such as chimeric and humanized monoclonal antibodies, comprising human and non-human portions, which can be prepared using standard recombinant DNA techniques, are also included within the scope of this disclosure. Such chimeric and humanized monoclonal antibodies can be produced using recombinant DNA techniques, such as those described in U.S. Patent No. 7,112,421; Better et al. (1988) Science 240:1041-1043; or Liu et al. (1987) Proceedings of the National Academy of Sciences 84,3439-3443.

[0061] Antibody variable domain sequence

[0062] The antibodies of the present disclosure may comprise the following heavy chain variable domain sequences: SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80,SEQ ID NO:81,SEQ ID NO:82,SEQ ID NO:83,SEQ ID NO:84,SEQ IDNO:85,SEQ ID NO:86,SEQ ID NO:87,SEQ ID NO:88,SEQ ID NO:89,SEQ ID NO:90,SEQ IDNO:91,SEQ ID NO:92,SEQ ID NO:93,SEQ ID NO:94,SEQ ID NO:95,SEQ ID NO:96,SEQ IDNO:97,SEQ ID NO:98,SEQ ID NO:99,SEQ ID NO:100,SEQ ID NO:101,SEQ ID NO:102,SEQID NO:103,SEQ ID NO:104,SEQ ID NO:105,SEQ ID NO:106,SEQ ID NO:107,SEQ ID NO:108,SEQ ID NO:109,SEQ ID NO:110,SEQ ID NO:111,SEQ ID NO:112,SEQ ID NO:113,SEQID NO:114,SEQ ID NO:115,SEQ ID NO:116,SEQ ID NO:117,SEQ ID NO:118,SEQ ID NO:119,SEQ ID NO:120,SEQ ID NO:121,SEQ ID NO:122,SEQ ID NO:123,SEQ ID NO:124,SEQID NO:125,SEQ ID NO:126,SEQ ID NO:127,SEQ ID NO:128,SEQ ID NO:129,SEQ ID NO:130,SEQ ID NO:131,SEQ ID NO:132,SEQ ID NO:133,SEQ ID NO:134,SEQ ID NO:135,SEQID NO:136,SEQ ID NO:137,SEQ ID NO:138,SEQ ID NO:139,SEQ ID NO:140,SEQ ID NO:141,SEQ ID NO:142,SEQ ID NO:143,SEQ ID NO:144,SEQ ID NO:145,SEQ ID NO:146,SEQID NO:147,SEQ ID NO:148,SEQ ID NO:149,SEQ ID NO:150,SEQ ID NO:151,SEQ ID NO:152,SEQ ID NO:153,SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, or SEQ ID NO:191. The heavy chain variable domain sequence may substantially comprise SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39,SEQ ID NO:40,SEQ ID NO:41,SEQ ID NO:42,SEQ IDNO:43,SEQ ID NO:44,SEQ ID NO:45,SEQ ID NO:46,SEQ ID NO:47,SEQ ID NO:48,SEQ IDNO:49,SEQ ID NO:50,SEQ ID NO:51,SEQ ID NO:52,SEQ ID NO:53,SEQ ID NO:54,SEQ IDNO:55,SEQ ID NO:56,SEQ ID NO:57,SEQ ID NO:58,SEQ ID NO:59,SEQ ID NO:60,SEQ IDNO:61,SEQ ID NO:62,SEQ ID NO:63,SEQ ID NO:64,SEQ ID NO:65,SEQ ID NO:66,SEQ IDNO:67,SEQ ID NO:68,SEQ ID NO:69,SEQ ID NO:70,SEQ ID NO:71,SEQ ID NO:72,SEQ IDNO:73,SEQ ID NO:74,SEQ ID NO:75,SEQ ID NO:76,SEQ ID NO:77,SEQ ID NO:78,SEQ IDNO:79,SEQ ID NO:80,SEQ ID NO:81,SEQ ID NO:82,SEQ ID NO:83,SEQ ID NO:84,SEQ IDNO:85,SEQ ID NO:86,SEQ ID NO:87,SEQ ID NO:88,SEQ ID NO:89,SEQ ID NO:90,SEQ IDNO:91,SEQ ID NO:92,SEQ ID NO:93,SEQ ID NO:94,SEQ ID NO:95,SEQ ID NO:96,SEQ IDNO:97,SEQ ID NO:98,SEQ ID NO:99,SEQ ID NO:100,SEQ ID NO:101,SEQ ID NO:102,SEQID NO:103,SEQ ID NO:104,SEQ ID NO:105,SEQ ID NO:106,SEQ ID NO:107,SEQ ID NO:108,SEQ ID NO:109,SEQ ID NO:110,SEQ ID NO:111,SEQ ID NO:112,SEQ ID NO:113,SEQID NO:114,SEQ ID NO:115,SEQ ID NO:116,SEQ ID NO:117,SEQ ID NO:118,SEQ ID NO:119,SEQ ID NO:120,SEQ ID NO:121,SEQ ID NO:122,SEQ ID NO:123,SEQ ID NO:124,SEQID NO:125,SEQ ID NO:126,SEQ ID NO:127,SEQ ID NO:128,SEQ ID NO:129,SEQ ID NO:130,SEQ ID NO:131,SEQ ID NO:132,SEQ ID NO:133,SEQ ID NO:134,SEQ ID NO:135,SEQID NO:136,SEQ ID NO:137,SEQ ID NO:138,SEQ ID NO:139,SEQ ID NO:140,SEQ ID NO:141,SEQ ID NO:142,SEQ ID NO:143,SEQ ID NO:144,SEQ ID NO:145,SEQ ID NO:146,SEQID NO:147,SEQ ID NO:148,SEQ ID NO:149,SEQ ID NO:150,SEQ ID NO:151,SEQ ID NO:152,SEQ ID NO:153,SEQ ID NO:154,SEQ ID NO:155,SEQ ID NO:156,SEQ ID NO:157,SEQID NO:158,SEQ ID NO:159,SEQ ID NO:160,SEQ ID NO:161,SEQ ID NO:162,SEQ ID NO:163,SEQ ID NO:164,SEQ ID NO:165,SEQ ID NO:166,SEQ ID NO:167,SEQ ID NO:168,SEQID NO:169,SEQ ID NO:170,SEQ ID NO:171,SEQ ID NO:172,SEQ ID NO:173,SEQ ID NO:174,SEQ ID NO:175,SEQ ID NO:176,SEQ ID NO:177,SEQ ID NO:178,SEQ ID NO:179,SEQID NO:180,SEQ ID NO:181,SEQ ID NO:182,SEQ ID NO:183,SEQ ID NO:184,SEQ ID NO:185,SEQ ID NO:186,SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, or SEQ ID NO:191.,

[0063] The antibodies of the present disclosure may comprise the following light chain variable domain sequences: SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, SEQ ID NO:242, SEQ ID NO:243, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO:246, SEQ ID NO:247, SEQ ID NO:248, SEQ ID NO:249, SEQ ID NO:250, SEQ ID NO:251, SEQ ID NO:252, SEQ ID NO:253, SEQ ID NO:254, SEQ ID NO:255, SEQ ID NO:256, SEQ ID NO:257, SEQ ID NO:258, SEQ ID NO:259, SEQ ID NO:260, SEQ ID NO:261,SEQ ID NO:262,SEQ ID NO:263,SEQ ID NO:264,SEQ IDNO:265,SEQ ID NO:266,SEQ ID NO:267,SEQ ID NO:268,SEQ ID NO:269,SEQ ID NO:270,SEQ ID NO:271,SEQ ID NO:272,SEQ ID NO:273,SEQ ID NO:274,SEQ ID NO:275,SEQ IDNO:276,SEQ ID NO:277,SEQ ID NO:278,SEQ ID NO:279,SEQ ID NO:280,SEQ ID NO:281,SEQ ID NO:282,SEQ ID NO:283,SEQ ID NO:284,SEQ ID NO:285,SEQ ID NO:286,SEQ IDNO:287,SEQ ID NO:288,SEQ ID NO:289,SEQ ID NO:290,SEQ ID NO:291,SEQ ID NO:292,SEQ ID NO:293,SEQ ID NO:294,SEQ ID NO:295,SEQ ID NO:296,SEQ ID NO:297,SEQ IDNO:298,SEQ ID NO:299,SEQ ID NO:300,SEQ ID NO:301,SEQ ID NO:302,SEQ ID NO:303,SEQ ID NO:304,SEQ ID NO:305,SEQ ID NO:306,SEQ ID NO:307,SEQ ID NO:308,SEQ IDNO:309,SEQ ID NO:310,SEQ ID NO:311,SEQ ID NO:312,SEQ ID NO:313,SEQ ID NO:314,SEQ ID NO:315,SEQ ID NO:316,SEQ ID NO:317,SEQ ID NO:318,SEQ ID NO:319,SEQ IDNO:320,SEQ ID NO:321,SEQ ID NO:322,SEQ ID NO:323,SEQ ID NO:324,SEQ ID NO:325,SEQ ID NO:326,SEQ ID NO:327,SEQ ID NO:328,SEQ ID NO:329,SEQ ID NO:330,SEQ IDNO:331,SEQ ID NO:332,SEQ ID NO:333,SEQ ID NO:334, SEQ ID NO:335, SEQ ID NO:336, SEQ ID NO:337, SEQ ID NO:338, SEQ ID NO:339, SEQ ID NO:340, SEQ ID NO:341, SEQ ID NO:342, SEQ ID NO:343, SEQ ID NO:344, SEQ ID NO:345, SEQ ID NO:346, SEQ ID NO:347, SEQ ID NO:348, SEQ ID NO:349, SEQ ID NO:350, SEQ ID NO:351, SEQ ID NO:352, SEQ ID NO:353, SEQ ID NO:354, SEQ ID NO:355, SEQ ID NO:356, SEQ ID NO:357, SEQ ID NO:358, SEQ ID NO:359, SEQ ID NO:360, SEQ ID NO:361, SEQ ID NO:362, SEQ ID NO:363, SEQ ID NO:364, SEQ ID NO:365, SEQ ID NO:366, SEQ ID NO:367, SEQ ID NO:368, SEQ ID NO:369, SEQ ID NO:370, SEQ ID NO:371, SEQ ID NO:372, SEQ ID NO:373, SEQ ID NO:374, SEQ ID NO:375, SEQ ID NO:376, SEQ ID NO:377, SEQ ID NO:378, SEQ ID NO:379, SEQ ID NO:380, or SEQ ID NO:381. The light chain variable domain sequence may substantially comprise SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213,SEQ ID NO:214,SEQ ID NO:215,SEQID NO:216,SEQ ID NO:217,SEQ ID NO:218,SEQ ID NO:219,SEQ ID NO:220,SEQ ID NO:221,SEQ ID NO:222,SEQ ID NO:223,SEQ ID NO:224,SEQ ID NO:225,SEQ ID NO:226,SEQID NO:227,SEQ ID NO:228,SEQ ID NO:229,SEQ ID NO:230,SEQ ID NO:231,SEQ ID NO:232,SEQ ID NO:233,SEQ ID NO:234,SEQ ID NO:235,SEQ ID NO:236,SEQ ID NO:237,SEQID NO:238,SEQ ID NO:239,SEQ ID NO:240,SEQ ID NO:241,SEQ ID NO:242,SEQ ID NO:243,SEQ ID NO:244,SEQ ID NO:245,SEQ ID NO:246,SEQ ID NO:247,SEQ ID NO:248,SEQID NO:249,SEQ ID NO:250,SEQ ID NO:251,SEQ ID NO:252,SEQ ID NO:253,SEQ ID NO:254,SEQ ID NO:255,SEQ ID NO:256,SEQ ID NO:257,SEQ ID NO:258,SEQ ID NO:259,SEQID NO:260,SEQ ID NO:261,SEQ ID NO:262,SEQ ID NO:263,SEQ ID NO:264,SEQ ID NO:265,SEQ ID NO:266,SEQ ID NO:267,SEQ ID NO:268,SEQ ID NO:269,SEQ ID NO:270,SEQID NO:271,SEQ ID NO:272,SEQ ID NO:273,SEQ ID NO:274,SEQ ID NO:275,SEQ ID NO:276,SEQ ID NO:277,SEQ ID NO:278,SEQ ID NO:279,SEQ ID NO:280,SEQ ID NO:281,SEQID NO:282,SEQ ID NO:283,SEQ ID NO:284,SEQ ID NO:285,SEQ ID NO:286,SEQ ID NO:287,SEQ ID NO:288,SEQ ID NO:289,SEQ ID NO:290,SEQ ID NO:291,SEQ ID NO:292,SEQID NO:293,SEQ ID NO:294,SEQ ID NO:295,SEQ ID NO:296,SEQ ID NO:297,SEQ ID NO:298,SEQ ID NO:299,SEQ ID NO:300,SEQ ID NO:301,SEQ ID NO:302,SEQ ID NO:303,SEQID NO:304,SEQ ID NO:305,SEQ ID NO:306,SEQ ID NO:307,SEQ ID NO:308,SEQ ID NO:309,SEQ ID NO:310,SEQ ID NO:311,SEQ ID NO:312,SEQ ID NO:313,SEQ ID NO:314,SEQID NO:315,SEQ ID NO:316,SEQ ID NO:317,SEQ ID NO:318,SEQ ID NO:319,SEQ ID NO:320,SEQ ID NO:321,SEQ ID NO:322,SEQ ID NO:323,SEQ ID NO:324,SEQ ID NO:325,SEQID NO:326,SEQ ID NO:327,SEQ ID NO:328,SEQ ID NO:329,SEQ ID NO:330,SEQ ID NO:331,SEQ ID NO:332,SEQ ID NO:333,SEQ ID NO:334,SEQ ID NO:335,SEQ ID NO:336,SEQID NO:337,SEQ ID NO:338,SEQ ID NO:339,SEQ ID NO:340,SEQ ID NO:341,SEQ ID NO:342,SEQ ID NO:343,SEQ ID NO:344,SEQ ID NO:345,SEQ ID NO:346,SEQ ID NO:347,SEQID NO:348,SEQ ID NO:349,SEQ ID NO:350,SEQ ID NO:351,SEQ ID NO:352,SEQ ID NO:353,SEQ ID NO:354,SEQ ID NO:355,SEQ ID NO:356,SEQ ID NO:357,SEQ ID NO:358,SEQID NO:359,SEQ ID NO:360,SEQ ID NO:361,SEQ ID NO:362,SEQ ID NO:363,SEQ ID NO:364,SEQ ID NO:365,SEQ ID NO:366,SEQ ID NO:367,SEQ ID NO:368,SEQ ID NO:369,SEQID NO:370,SEQ ID NO:371,SEQ ID NO:372,SEQ ID NO:373,SEQ ID NO:374,SEQ ID NO:375,SEQ ID NO:376,SEQ ID NO:377,SEQ ID NO:378,SEQ ID NO:379,SEQ ID NO:380,orSEQ ID NO:381.,

[0064] This disclosure also provides a variable domain sequence comprising at least 80%, at least 85%, at least 90%, or at least 95% identical to a sequence selected from the following: SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:3 ... NO:35,SEQ ID NO:36,SEQ ID NO:37,SEQ IDNO:38,SEQ ID NO:39,SEQ ID NO:40,SEQ ID NO:41,SEQ ID NO:42,SEQ ID NO:43,SEQ IDNO:44,SEQ ID NO:45,SEQ ID NO:46,SEQ ID NO:47,SEQ ID NO:48,SEQ ID NO:49,SEQ ID NO:50,SEQ ID NO:51,SEQ ID NO:52,SEQ ID NO:53,SEQ ID NO:54,SEQ ID NO:55,SEQ IDNO:56,SEQ ID NO:57,SEQ ID NO:58,SEQ ID NO:59,SEQ ID NO:60,SEQ ID NO:61,SEQ IDNO:62,SEQ ID NO:63,SEQ ID NO:64,SEQ ID NO:65,SEQ ID NO:66,SEQ ID NO:67,SEQ IDNO:68,SEQ ID NO:69,SEQ ID NO:70,SEQ ID NO:71,SEQ ID NO:72,SEQ ID NO:73,SEQ ID NO:74,SEQ ID NO:75,SEQ ID NO:76,SEQ ID NO:77,SEQ ID NO:78,SEQ ID NO:79,SEQ IDNO:80,SEQ ID NO:81,SEQ ID NO:82,SEQ ID NO:83,SEQ ID NO:84,SEQ ID NO:85,SEQ IDNO:86,SEQ ID NO:87,SEQ ID NO:88,SEQ ID NO:89,SEQ ID NO:90,SEQ ID NO:91,SEQ IDNO:92,SEQ ID NO:93,SEQ ID NO:94,SEQ ID NO:95,SEQ ID NO:96,SEQ ID NO:97,SEQ IDNO:98,SEQ ID NO:99,SEQ ID NO:100,SEQ ID NO:101,SEQ ID NO:102,SEQ ID NO:103,SEQ ID NO:104,SEQ ID NO:105,SEQ ID NO:106,SEQ ID NO:107,SEQ ID NO:108,SEQ IDNO:109,SEQ ID NO:110,SEQ ID NO:111,SEQ ID NO:112,SEQ ID NO:113,SEQ ID NO:114,SEQ ID NO:115,SEQ ID NO:116,SEQ ID NO:117,SEQ ID NO:118,SEQ ID NO:119,SEQ IDNO:120,SEQ ID NO:121,SEQ ID NO:122,SEQ ID NO:123,SEQ ID NO:124,SEQ ID NO:125,SEQ ID NO:126,SEQ ID NO:127,SEQ ID NO:128,SEQ ID NO:129,SEQ ID NO:130,SEQ IDNO:131,SEQ ID NO:132,SEQ ID NO:133,SEQ ID NO:134,SEQ ID NO:135,SEQ ID NO:136,SEQ ID NO:137,SEQ ID NO:138,SEQ ID NO:139,SEQ ID NO:140,SEQ ID NO:141,SEQ IDNO:142,SEQ ID NO:143,SEQ ID NO:144,SEQ ID NO:145,SEQ ID NO:146,SEQ ID NO:147,SEQ ID NO:148,SEQ ID NO:149,SEQ ID NO:150,SEQ ID NO:151,SEQ ID NO:152,SEQ ID NO:153,SEQ ID NO:154,SEQ ID NO:155,SEQ ID NO:156,SEQ ID NO:157,SEQ ID NO:158,SEQ ID NO:159,SEQ ID NO:160,SEQ ID NO:161,SEQ ID NO:162,SEQ ID NO:163,SEQ ID NO:164,SEQ ID NO:165,SEQ ID NO:166,SEQ ID NO:167,SEQ ID NO:168,SEQ ID NO:169,SEQ ID NO:170,SEQ ID NO:171,SEQ ID NO:172,SEQ ID NO:173,SEQ ID NO:174,SEQ IDNO:175,SEQ ID NO:176,SEQ ID NO:177,SEQ ID NO:178,SEQ ID NO:179,SEQ ID NO:180,SEQ ID SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, or SEQ ID NO:191. This disclosure also provides a variable domain sequence comprising at least 80%, at least 85%, at least 90%, or at least 95% identical sequences selected from the following: SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:191. ID NO:206,SEQ ID NO:207,SEQ ID NO:208,SEQ ID NO:209,SEQ ID NO:210,SEQ ID NO:211,SEQ ID NO:212,SEQ ID NO:213,SEQ ID NO:214,SEQ ID NO:215,SEQ ID NO:216,SEQ ID NO:217,SEQ ID NO:218,SEQ ID NO:219,SEQ ID NO:220,SEQ ID NO:221,SEQ ID NO:222,SEQ ID NO:223,SEQ ID NO:224,SEQ ID NO:225,SEQ ID NO:226,SEQ ID NO:227,SEQ IDNO:228,SEQ ID NO:229,SEQ ID NO:230,SEQ ID NO:231,SEQ ID NO:232,SEQ ID NO:233,SEQ ID NO:234,SEQ ID NO:235,SEQ ID NO:236,SEQ ID NO:237,SEQ ID NO:238,SEQ IDNO:239,SEQ ID NO:240,SEQ ID NO:241,SEQ ID NO:242,SEQ ID NO:243,SEQ ID NO:244,SEQ ID NO:245,SEQ ID NO:246,SEQ ID NO:247,SEQ ID NO:248,SEQ ID NO:249,SEQ IDNO:250,SEQ ID NO:251,SEQ ID NO:252,SEQ ID NO:253,SEQ ID NO:254,SEQ ID NO:255,SEQ ID NO:256,SEQ ID NO:257,SEQ ID NO:258,SEQ ID NO:259,SEQ ID NO:260,SEQ IDNO:261,SEQ ID NO:262,SEQ ID NO:263,SEQ ID NO:264,SEQ ID NO:265,SEQ ID NO:266,SEQ ID NO:267,SEQ ID NO:268,SEQ ID NO:269,SEQ ID NO:270,SEQ ID NO:271,SEQ IDNO:272,SEQ ID NO:273,SEQ ID NO:274,SEQ ID NO:275,SEQ ID NO:276,SEQ ID NO:277,SEQ ID NO:278,SEQ ID NO:279,SEQ ID NO:280,SEQ ID NO:281,SEQ ID NO:282,SEQ IDNO:283,SEQ ID NO:284,SEQ ID NO:285,SEQ ID NO:286,SEQ ID NO:287,SEQ ID NO:288,SEQ ID NO:289,SEQ ID NO:290,SEQ ID NO:291,SEQ ID NO:292,SEQ ID NO:293,SEQ IDNO:294,SEQ ID NO:295,SEQ ID NO:296,SEQ ID NO:297,SEQ ID NO:298,SEQ ID NO:299,SEQ ID NO:300,SEQ ID NO:301,SEQ ID NO:302,SEQ ID NO:303,SEQ ID NO:304,SEQ IDNO:305,SEQ ID NO:306,SEQ ID NO:307,SEQ ID NO:308,SEQ ID NO:309,SEQ ID NO:310,SEQ ID NO:311,SEQ ID NO:312,SEQ ID NO:313,SEQ ID NO:314,SEQ ID NO:315,SEQ IDNO:316,SEQ ID NO:317,SEQ ID NO:318,SEQ ID NO:319,SEQ ID NO:320,SEQ ID NO:321,SEQ ID NO:322,SEQ ID NO:323,SEQ ID NO:324,SEQ ID NO:325,SEQ ID NO:326,SEQ IDNO:327,SEQ ID NO:328,SEQ ID NO:329,SEQ ID NO:330,SEQ ID NO:331,SEQ ID NO:332,SEQ ID NO:333,SEQ ID NO:334,SEQ ID NO:335,SEQ ID NO:336,SEQ ID NO:337,SEQ IDNO:338,SEQ ID NO:339,SEQ ID NO:340,SEQ ID NO:341,SEQ ID NO:342,SEQ ID NO:343,SEQ ID NO:344,SEQ ID NO:345,SEQ ID NO:346,SEQ ID NO:347,SEQ ID NO:348,SEQ IDNO:349,SEQ ID NO:350,SEQ ID NO:351,SEQ ID NO:352,SEQ ID NO:353,SEQ ID NO:354,SEQ ID NO:355,SEQ ID NO:356,SEQ ID NO:357,SEQ ID NO:358,SEQ ID NO:359,SEQ IDNO:360,SEQ ID NO:361,SEQ ID NO:362,SEQ ID NO:363,SEQ ID NO:364,SEQ ID NO:365,SEQ ID NO:366,SEQ ID NO:367,SEQ ID NO:368,SEQ ID NO:369,SEQ ID NO:370,SEQ IDNO:371,SEQ ID NO:372,SEQ ID NO:373,SEQ ID NO:374,SEQ ID NO:375,SEQ ID NO:376,SEQ ID NO:377,SEQ ID NO:378,SEQ ID NO:379,SEQ ID NO:380,or SEQ ID NO:381.75,SEQ ID NO:376,SEQ ID NO:377,SEQ ID NO:378,SEQ ID NO:379,SEQ ID NO:380,or SEQID NO:381.,

[0065] This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:35, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:296. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:77, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:278. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:175, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:353. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:97, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:354. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:142, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:356.

[0066] This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:131, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:337. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:173, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:361. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:47, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:345. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the same heavy chain variable domain sequence as SEQ ID NO:19, and at least 80%, 85%, 90%, or 95% of the same light chain variable domain sequence as SEQ ID NO:296. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the same heavy chain variable domain sequence as SEQ ID NO:37, and at least 80%, 85%, 90%, or 95% of the same light chain variable domain sequence as SEQ ID NO:297. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the same heavy chain variable domain sequence as SEQ ID NO:105, and at least 80%, 85%, 90%, or 95% of the same light chain variable domain sequence as SEQ ID NO:235. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:21, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:262. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:94, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:201.This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:21, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:260. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:93, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:248. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:80, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:281. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:56, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:197. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:62, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:206. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:50, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:295. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:10, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:296. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:172, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:244.This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:115, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:307. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:29, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:296. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:104, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:310.

[0067] This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:12, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:296. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:143, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:234. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:133, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:230. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:185, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:371. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:5, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:274. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:152, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:266. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:152, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:338. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:171, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:245.This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:31, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:297. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:174, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:358.

[0068] This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:21, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:342. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:27, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:250. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:119, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:202. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:124, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:309. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:135, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:212. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:111, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:237. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:125, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:362. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:81, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:276.This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:121, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:381. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:54, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:261.

[0069] This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:101, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:242. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:116, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:290. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:106, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:235. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:44, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:240. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:187, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:378. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:89, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:268. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:48, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:299. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:8, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:259.This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:75, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:228. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:51, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:297.

[0070] This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:46, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:343. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:76, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:289. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:59, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:195. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:25, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:369. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:110, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:267. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:24, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:368. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:147, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:317. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:44, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:249.This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:134, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:216.

[0071] This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:136, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:226. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:189, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:308. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:78, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:277. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:32, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:297. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:13, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:296. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:13, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:291. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:83, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:287. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:23, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:258.This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:150, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:327. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:71, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:196.

[0072] This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:157, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:223. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:66, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:224. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:30, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:297. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:118, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:194. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:155, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:324. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:43, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:293. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:140, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:359. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:146, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:321.This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:23, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:264. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:17, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:292.

[0073] This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:127, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:331. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:23, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:257. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:191, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:315. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:22, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:255. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:42, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:263. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:61, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:198. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:33, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:297. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:178, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:232.This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:130, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:210. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:85, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:279.

[0074] This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:40, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:258. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:95, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:200. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:108, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:238. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:65, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:193. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:49, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:296. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:20, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:251. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:87, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:334. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:162, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:346.This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:161, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:366. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:64, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:208.

[0075] This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:64, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:326. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:21, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:252. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:141, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:356. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:21, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:256. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:70, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:207. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:153, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:328. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:122, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:269. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:156, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:311.This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:84, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:284.

[0076] This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:159, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:367. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:153, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:323. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:128, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:213. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:67, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:227. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:92, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:241. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:21, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:236. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:23, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:229. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:166, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:363.This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:11, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:300. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:15, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:297.

[0077] This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the same heavy chain variable domain sequence as SEQ ID NO:103, and at least 80%, 85%, 90%, or 95% of the same light chain variable domain sequence as SEQ ID NO:319. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the same heavy chain variable domain sequence as SEQ ID NO:69, and at least 80%, 85%, 90%, or 95% of the same light chain variable domain sequence as SEQ ID NO:205. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the same heavy chain variable domain sequence as SEQ ID NO:53, and at least 80%, 85%, 90%, or 95% of the same light chain variable domain sequence as SEQ ID NO:263. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:183, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:375. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:9, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:265. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:16, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:303. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:183, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:341. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:55, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:261.This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:190, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:377. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:23, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:254.

[0078] This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:176, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:379. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:34, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:314. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:154, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:335. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:160, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:273. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:102, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:218. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:102, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:320. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:158, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:308. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:5, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:272.This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:79, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:286. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:74, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:285.

[0079] This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:180, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:373. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:18, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:296. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:182, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:372. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:113, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:332. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:57, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:204. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:26, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:260. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:26, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:344. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:179, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:203.This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:99, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:357.

[0080] This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:91, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:246. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:45, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:250. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:52, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:294. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:41, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:260. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:177, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:380. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:28, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:302. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:112, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:233. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:163, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:351.This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:6, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:192. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:164, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:365.

[0081] This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:183, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:374. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:21, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:253. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:60, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:222. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:126, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:220. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:72, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:247. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:169, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:271. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:88, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:322. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:168, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:273.This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:184, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:347. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:50, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:260.

[0082] This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:138, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:352. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:109, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:239. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:40, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:262. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:188, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:306. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:129, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:337. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:144, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:221. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:103, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:318. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:100, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:301.This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:63, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:336.

[0083] This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:27, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:254. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:14, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:298. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:117, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:316. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:181, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:349. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:153, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:329. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:120, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:340. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:21, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:373. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:181, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:348.This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:86, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:282. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:98, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:360.

[0084] This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:58, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:199. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:38, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:313. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:68, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:219. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:107, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:238. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:132, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:231. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:137, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:214. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:98, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:217. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:114, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:217.This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:90, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:243. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:7, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:225.

[0085] This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:7, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:376. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:186, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:370. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:39, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:270. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:145, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:355. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:139, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:356. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:64, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:209. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:123, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:312. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:36, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:305.This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:148, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:266. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:148, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:339.

[0086] This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:16, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:304. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:16, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:192. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:73, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:283. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:151, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:325. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:149, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:337. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:149, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:211. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:151, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:215. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:83, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:280.This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:167, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:275.

[0087] This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:83, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:288. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:165, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:364. This disclosure also provides antibodies comprising at least 80%, at least 85%, at least 90%, or at least 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:82, and at least 80%, at least 85%, at least 90%, or at least 95% of the light chain variable domain sequence identical to that of SEQ ID NO:282. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:163, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:350. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:170, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:330. This disclosure also provides antibodies comprising at least 80%, 85%, 90%, or 95% of the heavy chain variable domain sequence identical to that of SEQ ID NO:96, and at least 80%, 85%, 90%, or 95% of the light chain variable domain sequence identical to that of SEQ ID NO:333.

[0088] The antibodies provided in this disclosure, after appropriate humanization, can be used to treat and prevent SARS-CoV-2 infection by blocking the binding of the S protein to human angiotensin-converting enzyme 2 (huACE2). Studies have shown that such binding events are part of a multi-step process in which the virus enters cells and multiplies (Hoffmann et al., 2020). The antibodies provided in this disclosure, after appropriate humanization, can be used to provide passive immunity to frontline healthcare workers to prevent infection.

[0089] For information on the discovery and development of antibody therapies against the SARS-CoV-2S protein that are well known in the art, please see U.S. Patent No. 10,975,139, which describes the discovery and development of antibody therapies against SARS-CoV-2, the entire contents of which are incorporated herein by reference.

[0090] Pharmaceutical Composition

[0091] Pharmaceutical compositions comprising antibodies or antibody fragments of the present disclosure are also considered, and may be used in the methods disclosed herein.

[0092] The pharmaceutical composition may comprise one or more antibodies or antibody fragments as described in this disclosure, as well as a pharmaceutically acceptable carrier or excipient. While the carrier or excipient may facilitate drug administration, it should not itself induce antibodies harmful to the subject or individual receiving the composition; nor should it be toxic. Suitable carriers may be larger, slowly metabolized macromolecules, such as proteins, peptides, liposomes, polysaccharides, polylactic acid, polyglycolic acid, polyamino acids, amino acid copolymers, and inactive viral particles, and are known to those skilled in the art.

[0093] The antibodies or antigen-binding fragments described in this disclosure, or the pharmaceutical compositions disclosed herein, can be administered via various routes, including but not limited to oral, intravenous, intramuscular, intraarterial, intramedullary, intraperitoneal, intrathecal, intracardiac, transdermal, percutaneous, local, subcutaneous, intranasal, intraenteral, sublingual, vaginal, or rectal routes. Typically, the therapeutic compositions can be prepared as injectable liquid solutions or suspensions. They can also be prepared in a solid form suitable for dissolving or suspending in a liquid solvent prior to injection.

[0094] In one embodiment, the antibody or its antigen-binding fragment or pharmaceutical composition is administered intravenously. In another embodiment, the antibody or its antigen-binding fragment or pharmaceutical composition is administered via intravenous infusion.

[0095] Direct delivery of the composition is typically accomplished via injection, subcutaneous, intraperitoneal, intravenous, or intramuscular administration, or delivery into the interstitial space. The composition may also be delivered to the site of lesion.

[0096] Dosage-based therapy can be administered via single-dose or multiple-dose regimens. Antibody-based medications are known to provide guidelines regarding frequency of use, such as whether the medication should be taken daily, weekly, monthly, etc. Frequency and dosage may also depend on the severity of symptoms.

[0097] It should be understood that the active ingredient in the composition will be an antibody molecule, antibody fragment, or its variants and derivatives. Therefore, it is readily degraded in the gastrointestinal tract. Consequently, if the composition is administered via the gastrointestinal route, it will need to contain a formulation that protects the antibody from degradation but releases it upon absorption in the gastrointestinal tract.

[0098] The methods disclosed herein may use antibodies or antigen-binding fragments thereof as described above, which may be used alone or in combination with other pharmaceutically active compounds to treat diseases such as those described above. Additional pharmaceutically active compounds may be administered simultaneously (in the same or different dosage forms) or sequentially. Therefore, in one embodiment, this disclosure includes a method of treating a disease by administering to a subject a therapeutically effective amount of the disclosed antibody or antigen-binding fragment thereof, along with one or more additional pharmaceutically active compounds.

[0099] Table 1 provides a summary of the SARS-CoV-2S protein-specific antibodies described in this disclosure:

[0100] Example

[0101] The following embodiments are provided to provide a complete description of how to make and use this disclosure to those skilled in the art, and are not intended to limit the scope of the disclosure as the inventors believe it to be, nor are they intended to represent all or only experiments that can be performed. We have made every effort to ensure the accuracy of the figures used (such as quantities, temperatures, etc.), but some experimental errors and biases should also be taken into account.

[0102] Unless otherwise stated, parts refer to parts by weight, molecular weight refers to weight average molecular weight, temperature refers to degrees Celsius, and pressure refers to atmospheric pressure or near atmospheric pressure.

[0103] Example 1: Isolation of mouse anti-SARS-CoV-2S protein antibody and production of single-cell suspension

[0104] Recombinant SARS-CoV-2S1 protein (His tag, catalog number: 40591-V08H, Sino Biological, Beijing, China, SEQ ID NO:2) was used to immunize young CD1 mice, each mouse in the Sigma Adjuvant system. A rapid immunization protocol using an antibody solution (Santa Clara, California) was employed (Sigma-Aldrich, St. Louis, Missouri), immunizing patients with 80 μg of protein over 35 days. Lymph nodes were harvested on day 35. A single-cell suspension of the lymph nodes was generated, and the suspension was filtered using a 70 μm mesh (BD Bioscience) to remove clumps.

[0105] Plasma cell isolation, antibody capture, and antigen interrogation

[0106] Filtered lymphocyte suspensions were enriched using a kit based on CD138 (Miltenyi, Auburn, California) cell surface expression to obtain plasma cells actively secreting IgG. Freshly enriched plasma cells were deposited onto a PDMS instrument using the method described in U.S. Patent No. 9,328,172, allowing single-cell deposition into the microwells of the instrument. Antibodies secreted by each plasma cell were captured onto a derived microscope slide. The antibody-captured slides were interrogated using different concentrations of the full-length SARS-CoV-2 S protein labeled with His (ACROBiosystems, Beijing, China, Catalog No.: SPN-C52H4, SEQ ID NO:3) and reverse-selected using the His-labeled SARS-CoV Spike / S1 protein (Sino Biological, Beijing, China, Catalog No.: 40150-V08B1, SEQ ID NO:4) to identify antigen-specific antibody-secreting cells, detecting potentially broadly recognizable antibodies and / or neutralizing antibodies. Use the kit (AnaSpec, Fremont, CA, AS-72046, AnaTag) TM HiLyte TM Use the Fluor 555 Micro Protein Labeling Kit (super convenient!) for labeling.

[0107] mRNA capture

[0108] After antibody capture, the culture medium was removed and replaced with lysis buffer, and then the tops of the microwells were rapidly sealed with a custom oligonucleotide microarray (Agilent, Santa Clara, CA). This procedure was previously described in U.S. Patent No. 9,328,172. The custom oligonucleotide microarray was prepared such that each feature not only contained a unique tag specifying its coordinates, but also capture probes for all subclasses (1, 2a, 2b, and 3) of the mouse IgG heavy chain and mouse Igκ light chain.

[0109] cDNA synthesis, PCR amplification, and next-generation sequencing

[0110] The mRNA captured on the custom microarray is further processed to synthesize cDNA for each mRNA, which includes the original unique tag on each feature.

[0111] The cDNA was then amplified using Taq polymerase (Promega, Madison, Wisconsin) and a suitable primer set to amplify the following genes: the variable domain of the IgG heavy chain subclass and the variable domain of the Igκ light chain. While these fragments of each gene are now released from the cell, they are all tagged with unique tags from a custom oligonucleotide microarray indicating their start position. The amplicons were further manipulated to ligate suitable sequences at both ends, enabling sequencing on a 2x250 bp chemi (length) sequence using an Illumina MiSeq instrument at SeqMatic LLC (Fremont, California).

[0112] Bioinformatics analysis of images and DNA sequences

[0113] Process sequencing reads from MiSeq, identify the tags embedded in each read, and convert them into coordinates.

[0114] Coordinates were plotted to generate a synthesis map of the recovered mRNA. Most coordinates formed clusters, specifying the location of the cell of origin for the recovered mRNA sequence. Next, CDR3 motifs present in each coordinate reading were identified and compared based on clusters that matched the locations of antibody spots revealed by a suitable fluorescently labeled second antibody. Identical or nearly identical CDR3s in a given antibody spot were grouped together to form a consistent V-shape. H and V L Sequence pairs. Identification of V sequences containing identified CDR3. H or V L The remaining part of the sequence will assemble the relevant sequencing reads into V. H and V L The full-length cDNA sequence. Affinity measurements associated with each antigen-specific antibody spot are correlated with this pair of full-length cDNA.

[0115] Example 2: Molecular reconstruction and recombinant expression of anti-SARS-CoV-2S antibodies

[0116] Service providers will pair V based on known technologies H and V L The anti-SARS-CoV-2S antibody sequence was used to synthesize the corresponding gene fragment. The obtained gene fragment was cloned into a suitable plasmid vector and transfected into a suitable mammalian host (e.g., HEK293) for recombinant expression to produce an antibody preparation in full IgG form. The antibody preparation was characterized by measuring OD280 to assess the amount produced and by gel electrophoresis on PAGE to assess the size of the produced antibody chains.

[0117] Example 3: Characterization of recombinant anti-SARS-CoV-2S antibody

[0118] Selected subgroups of recombinant anti-SARS-CoV-2S antibodies were expressed using methods known in the art, and their affinity for the antibodies against His-labeled recombinant SARS-CoV-2S1 protein (catalog number: 40591-V08H, Sino Biological, Beijing, China, SEQ ID NO:2) and His-labeled recombinant full-length SARS-CoV-2S protein (ACROBiosystems, Beijing, China, catalog number: SPN-C52H4, SEQ ID NO:3) was assessed on a biofilm layer interferometry (BLI) instrument (e.g., Octet RED96e). The affinity measurement results for these two proteins are shown in Table 2.

[0119] Example 4: ELISA analysis of SARS-CoV-2S protein in patient plasma

[0120] An ELISA assay for detecting SARS-CoV-2S protein in patient plasma will be developed. In short, a first-predicted anti-SARS-CoV-2S protein antibody from this disclosure will be used as a capture antibody to coat 96-well polystyrene microplates.

[0121] The plates were then washed six times with PBS containing 0.01% Tween 20, blocked with BSA in PBS containing 0.01% Tween 20 at 37°C for 1 to 3 hours, and washed with PBS containing 0.01% Tween 20. 100 μL of plasma from the patient was added to each well of a 96-well polystyrene microplate.

[0122] The mixture will then be incubated at room temperature for two hours. After horseradish peroxidase-enzyme conjugation using standard techniques, the SARS-CoV-2S protein will be detected using a second predetermined anti-SARS-CoV-2S protein antibody from this disclosure, which has a different epitope from the first predetermined anti-SARS-CoV-2S protein antibody. The plate will be incubated for 12 hours. The wells will then be washed six times with PBS containing 0.01% Tween 20. 100 units of matrix will be added for color development, and the plate will be incubated for 15 to 30 minutes with continuous shaking. The reaction will then be terminated with 15 μL of sodium chloride, and the plate will be read at a wavelength of 450 nm. A standard curve will be generated using serial dilutions of known amounts of recombinant SARS-CoV-2S protein.

[0123] Example 5: A lateral flow immunoassay device for detecting SARS-CoV-2

[0124] The following tests are designed to detect viral antigens in patient specimens using an immunochromatographic assay configured on a cross-flow device.

[0125] This method can detect serum samples from suspected SARS-CoV-2 patients. A 20 μL serum sample can be used. After applying the sample for 30 seconds, 100 μL of PBS buffer (0.01 M phosphate buffer, 0.0027 M potassium chloride, and 0.137 M sodium chloride, pH 7.4) is applied. The sample will move through the application area, the conjugate pad, and the nitrocellulose band until it reaches the capture area. Detection or reaction is allowed for 30 minutes, followed by visual analysis, i.e., two red lines, one at the top of the band and the other at the bottom (control line and test line, respectively), indicating the presence of viral antigens detected by the antibodies disclosed in this disclosure.

[0126] Table 2

[0127]

[0128] Epitope identification was performed using methods known in the art via BLI detection to further characterize the subgroups recombinantly expressing anti-SARS-CoV-2S antibodies. Epitope segment diagram is shown below. Figure 1 As shown.

[0129] Neutralizing activity was assessed using a SARS-CoV-2 reporter virus particle formulation (RVP, IntegralMolecular, Philadelphia, PA, USA) representing the D614G variant, further characterizing the subgroups recombinantly expressing anti-SARS-CoV-2S antibodies. RVPs are replication-defective pseudotyped viral particles capable of safely detecting viral infectivity and neutralization. These RVPs carry a luciferase as a reporter gene, and infection of suitable host cells (stable 293 cells stably transfected with a human ACE2 gene construct) will exhibit bioluminescence.

[0130] Antibodies that prevent RVP from entering host cells will not show any signal. The results of such neutralization assays are as follows: Figure 2 As shown.

[0131] This disclosure lists the antibodies recovered from the aforementioned antibody activities. The CDR sequence and V of the anti-SARS-CoV-2S antibody described in this disclosure are also included. H and V L The sequences are described in Tables 3 and 4, respectively.

[0132] Table 3

[0133]

[0134]

[0135]

[0136]

[0137]

[0138]

[0139]

[0140] Table 4

[0141]

[0142]

[0143]

[0144]

[0145]

[0146]

[0147]

[0148]

[0149]

[0150]

[0151]

[0152]

[0153]

[0154]

[0155]

[0156] The foregoing has only illustrated the principles of this disclosure. It should be understood that those skilled in the art will be able to design various arrangements, which, while not explicitly described or shown herein, embody the principles of this disclosure and are within the spirit and scope of these principles. Furthermore, all embodiments and conditional language described in this disclosure are primarily intended to aid the reader in understanding the principles of this disclosure and the concepts contributed by the inventors to advance the technology, and should be interpreted as not being limited to the specific embodiments and conditions described herein. Moreover, all statements describing the principles, aspects, and embodiments of this disclosure and their specific examples are intended to cover their structural and functional equivalents. Furthermore, such equivalents are intended to include both currently known equivalents and those developed in the future, i.e., any element developed to perform the same function, regardless of its structure. Therefore, the scope of this disclosure is not intended to be limited to the exemplary embodiments shown and described herein. Rather, the scope and spirit of this disclosure are embodied in the appended claims.

[0157] References

[0158] Bisht, H., Roberts, A., Vogel, L., Bukreyev, A., Collins, PL, Murphy, BR, Subbarao, K., and Moss, B. (2004). Attenuated vaccinia virus expressing the spike protein of severe acute respiratory syndrome coronavirus protectively confers immunity in mice. Proceedings of the National Academy of Sciences 101, 6641–6646.

[0159] Bosch, BJ, van der Zee, R., de Haan, CAM, and Rottier, PJM (2003). Coronavirus spike protein is a type I viral fusion protein: structural and functional characteristics of the fusion core complex. J.Virol. 77, 8801-8811.

[0160] Buchholz, UJ, Bukreyev, A., Yang, L., Lamirande, EW, Murphy, BR, Subbarao, K., and Collins, PL (2004). Contribution of structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proceedings of the National Academy of Sciences of the United States of America 101, 9804–9809.

[0161] Chan, JF-W., Yuan, S., Kok, K.-H., To, KK-W., Chu, H., Yang, J., Xing, F., Liu, J., Yip, CC-Y., Poon, RW-S., et al. (2020). Familial pneumonia associated with the 2019 novel coronavirus, demonstrating human-to-human transmission: a family cluster study. The Lancet 395, 514–523.

[0162] Cheng, Y., Wong, R., Soo, YOY, Wong, WS, Lee, CK, Ng, MHL, Chan, P., Wong, KC, Leung, CB, and Cheng, G. (2005). Application of convalescent plasma therapy in SARS patients in Hong Kong. Eur. J. Clin. Microbiol. Infect. Dis. 24, 44-46.

[0163] Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., et al. (2020). Efficacy of convalescent plasma therapy in patients with severe COVID-19. Proceedings of the National Academy of Sciences of the United States of America 202004168.

[0164] Greenough, TC; Babcock, GJ; Roberts, A.; Hernandez, HJ; Thomas, Jr.; WD; Coccia, JA; Graziano, RF; Srinivasan, M.; Lowy, I.; Finberg, RW., et al. (2005). Development and characterization of neutralizing human monoclonal antibodies against severe acute respiratory syndrome-associated coronaviruses, providing effective immunoprophylaxis in mice. Journal of Infectious Diseases 191, 507-514.

[0165] He, Y., Lu, H., Siddiqui, P., Zhou, Y., and Jiang, S. (2005a). The receptor-binding domain of the spike protein of SARS-CoV contains multiple conformation-dependent epitopes that can induce highly potent neutralizing antibodies. J. Immunol. Baltim. Md 1950 174, 4908–4915.

[0166] He, Y., Zhu, Q., Liu, S., Zhou, Y., Yang, B., Li, J., and Jiang, S. (2005b). Key neutralizing determinants for identifying SARS-associated coronaviruses: their importance for designing SARS vaccines. Virology 334, 74–82.

[0167] Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, TS., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020). SARS-CoV-2 cell entry is ACE2 and TMPRSS2 dependent and blocked by a clinically proven protease inhibitor. *Cell*.

[0168] Hofmann,H.,Hattermann,K.,Marzi,A.,Gramberg,T.,Geier,M.,Krumbiegel,M.,Kuate,S., K., Niedrig, M., and S. (2004). The S protein of severe acute respiratory syndrome-associated coronavirus mediates viral entry into hepatocellular carcinoma cell lines and is targeted by neutralizing antibodies from infected patients. J.Virol. 78, 6134-6142.

[0169] Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X. et al. (2020). Clinical characteristics of patients infected with the novel coronavirus in Wuhan, China in 2019. The Lancet 395, 497-506.

[0170] Li, F. (2016). Structure, function, and evolution of the coronavirus spike protein. Annu. Rev. Virol. 3, 237-261.

[0171] Sui, J., Li, W., Roberts, A., Matthews, LJ, Murakami, A., Vogel, L., Wong, SK, Subbarao, K., Farzan, M., and Marasco, WA (2005). Evaluation of the immunoprophylactic effect of human monoclonal antibody 80R against severe acute respiratory syndrome using animal studies, epitope localization, and spike mutant analysis. J. Virol. 79, 5900-5906.

[0172] Walls, AC, Tortorici, MA, Snijder, J., Xiong, X., Bosch, B.-J., Rey, FA, and Veesler, D. (2017). Structural conformational changes in the coronavirus spike glycoprotein promote membrane fusion. Proceedings of the National Academy of Sciences 114, 11157-11162.

[0173] Wang, C., Horby, PW, Hayden, FG, and Gao, GF (2020). The novel coronavirus pneumonia outbreak of global health concern. The Lancet 395, 470-473.

[0174] Wei, WE (2020). Presymptomatic transmission of SARS-CoV-2 from January 23 to March 16, 2020 - Singapore. MMWR Morb.Mortal.Wkly.Rep.69.

[0175] Yang, Z., Kong, W., Huang, Y., Roberts, A., Murphy, BR., Subbarao, K., and Nabel, GJ (2004). DNA vaccine induces neutralizing and protective immunity against SARS coronavirus in mice. Nature 428: 561-564.

[0176] Yang, Z., Werner, HC, Kong, W., Leung, K., Traggiai, E., Lanzavecchia, A., and Nabel, GJ (2005). Escape-neutralizing antibodies against novel severe acute respiratory syndrome coronaviruses. Proceedings of the National Academy of Sciences 102, 797–801.

[0177] Zhang, L., and Liu, Y. (2020). Potential interventions in China for the novel coronavirus: a systematic review. Journal of Medical Virology - 92, 479-490. sequence list <110> Single-cell technology company Beijing Baipus Biotechnology Co., Ltd. <120> Anti-SARS-CoV-2 spike protein antibody <130> SCT0013-401-PC <150> US 63 / 015,037 <151> 2020-04-24 <160> 784 <170> PatentIn Version 3.5 <210> 1 <211> 1273 <212> PRT <213> SARS-CoV-2 <400> 1 Met Phe Val Phe Leu Val Leu Leu Pro Leu Val Ser Ser Gln Cys Val 1 5 10 15 Asn Leu Thr Thr Arg Thr Gln Leu Pro Pro Ala Tyr Thr Asn Ser Phe 20 25 30 Thr Arg Gly Val Tyr Tyr Pro Asp Lys Val Phe Arg Ser Ser Val Leu 35 40 45 His Ser Thr Gln Asp Leu Phe Leu Pro Phe Phe Ser Asn Val Thr Trp 50 55 60 Phe His Ala Ile His Val Ser Gly Thr Asn Gly Thr Lys Arg Phe Asp 65 70 75 80 Asn Pro Val Leu Pro Phe Asn Asp Gly Val Tyr Phe Ala Ser Thr Glu 85 90 95 Lys Ser Asn Ile Ile Arg Gly Trp Ile Phe Gly Thr Thr Leu Asp Ser 100 105 110 Lys Thr Gln Ser Leu Leu Ile Val Asn Asn Ala Thr Asn Val Val Ile 115 120 125 Lys Val Cys Glu Phe Gln Phe Cys Asn Asp Pro Phe Leu Gly Val Tyr 130 135 140 Tyr His Lys Asn Asn Lys Ser Trp Met Glu Ser Glu Phe Arg Val Tyr 145 150 155 160 Ser Ser Ala Asn Asn Cys Thr Phe Glu Tyr Val Ser Gln Pro Phe Leu 165 170 175 Met Asp Leu Glu Gly Lys Gln Gly Asn Phe Lys Asn Leu Arg Glu Phe 180 185 190 Val Phe Lys Asn Ile Asp Gly Tyr Phe Lys Ile Tyr Ser Lys His Thr 195 200 205 Pro Ile Asn Leu Val Arg Asp Leu Pro Gln Gly Phe Ser Ala Leu Glu 210 215 220 Pro Leu Val Asp Leu Pro Ile Gly Ile Asn Ile Thr Arg Phe Gln Thr 225 230 235 240 Leu Leu Ala Leu His Arg Ser Tyr Leu Thr Pro Gly Asp Ser Ser Ser 245 250 255 Gly Trp Thr Ala Gly Ala Ala Ala Tyr Tyr Val Gly Tyr Leu Gln Pro 260 265 270 Arg Thr Phe Leu Leu Lys Tyr Asn Glu Asn Gly Thr Ile Thr Asp Ala 275 280 285 Val Asp Cys Ala Leu Asp Pro Leu Ser Glu Thr Lys Cys Thr Leu Lys 290 295 300 Ser Phe Thr Val Glu Lys Gly Ile Tyr Gln Thr Ser Asn Phe Arg Val 305 310 315 320 Gln Pro Thr Glu Ser Ile Val Arg Phe Pro Asn Ile Thr Asn Leu Cys 325 330 335 Pro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala Ser Val Tyr Ala 340 345 350 Trp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr Ser Val Leu 355 360 365 Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly Val Ser Pro 370 375 380 Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala Asp Ser Phe 385 390 395 400 Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro Gly Gln Thr Gly 405 410 415 Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe Thr Gly Cys 420 425 430 Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys Val Gly Gly Asn 435 440 445 Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu Lys Pro Phe 450 455 460 Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser Thr Pro Cys 465 470 475 480 Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu Gln Ser Tyr Gly 485 490 495 Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr Arg Val Val Val 500 505 510 Leu Ser Phe Glu Leu Leu His Ala Pro Ala Thr Val Cys Gly Pro Lys 515 520 525 Lys Ser Thr Asn Leu Val Lys Asn Lys Cys Val Asn Phe Asn Phe Asn 530 535 540 Gly Leu Thr Gly Thr Gly Val Leu Thr Glu Ser Asn Lys Lys Phe Leu 545 550 555 560 Pro Phe Gln Gln Phe Gly Arg Asp Ile Ala Asp Thr Thr Asp Ala Val 565 570 575 Arg Asp Pro Gln Thr Leu Glu Ile Leu Asp Ile Thr Pro Cys Ser Phe 580 585 590 Gly Gly Val Ser Val Ile Thr Pro Gly Thr Asn Thr Ser Asn Gln Val 595 600 605 Ala Val Leu Tyr Gln Asp Val Asn Cys Thr Glu Val Pro Val Ala Ile 610 615 620 His Ala Asp Gln Leu Thr Pro Thr Trp Arg Val Tyr Ser Thr Gly Ser 625 630 635 640 Asn Val Phe Gln Thr Arg Ala Gly Cys Leu Ile Gly Ala Glu His Val 645 650 655 Asn Asn Ser Tyr Glu Cys Asp Ile Pro Ile Gly Ala Gly Ile Cys Ala 660 665 670 Ser Tyr Gln Thr Gln Thr Asn Ser Pro Arg Arg Ala Arg Ser Val Ala 675 680 685 Ser Gln Ser Ile Ile Ala Tyr Thr Met Ser Leu Gly Ala Glu Asn Ser 690 695 700 Val Ala Tyr Ser Asn Asn Ser Ile Ala Ile Pro Thr Asn Phe Thr Ile 705 710 715 720 Ser Val Thr Thr Glu Ile Leu Pro Val Ser Met Thr Lys Thr Ser Val 725 730 735 Asp Cys Thr Met Tyr Ile Cys Gly Asp Ser Thr Glu Cys Ser Asn Leu 740 745 750 Leu Leu Gln Tyr Gly Ser Phe Cys Thr Gln Leu Asn Arg Ala Leu Thr 755 760 765 Gly Ile Ala Val Glu Gln Asp Lys Asn Thr Gln Glu Val Phe Ala Gln 770 775 780 Val Lys Gln Ile Tyr Lys Thr Pro Pro Ile Lys Asp Phe Gly Gly Phe 785 790 795 800 Asn Phe Ser Gln Ile Leu Pro Asp Pro Ser Lys Pro Ser Lys Arg Ser 805 810 815 Phe Ile Glu Asp Leu Leu Phe Asn Lys Val Thr Leu Ala Asp Ala Gly 820 825 830 Phe Ile Lys Gln Tyr Gly Asp Cys Leu Gly Asp Ile Ala Ala Arg Asp 835 840 845 Leu Ile Cys Ala Gln Lys Phe Asn Gly Leu Thr Val Leu Pro Pro Leu 850 855 860 Leu Thr Asp Glu Met Ile Ala Gln Tyr Thr Ser Ala Leu Leu Ala Gly 865 870 875 880 Thr Ile Thr Ser Gly Trp Thr Phe Gly Ala Gly Ala Ala Leu Gln Ile 885 890 895 Pro Phe Ala Met Gln Met Ala Tyr Arg Phe Asn Gly Ile Gly Val Thr 900 905 910 Gln Asn Val Leu Tyr Glu Asn Gln Lys Leu Ile Ala Asn Gln Phe Asn 915 920 925 Ser Ala Ile Gly Lys Ile Gln Asp Ser Leu Ser Ser Thr Ala Ser Ala 930 935 940 Leu Gly Lys Leu Gln Asp Val Val Asn Gln Asn Ala Gln Ala Leu Asn 945 950 955 960 Thr Leu Val Lys Gln Leu Ser Ser Asn Phe Gly Ala Ile Ser Ser Val 965 970 975 Leu Asn Asp Ile Leu Ser Arg Leu Asp Lys Val Glu Ala Glu Val Gln 980 985 990 Ile Asp Arg Leu Ile Thr Gly Arg Leu Gln Ser Leu Gln Thr Tyr Val 995 1000 1005 Thr Gln Gln Leu Ile Arg Ala Ala Glu Ile Arg Ala Ser Ala Asn 1010 1015 1020 Leu Ala Ala Thr Lys Met Ser Glu Cys Val Leu Gly Gln Ser Lys 1025 1030 1035 Arg Val Asp Phe Cys Gly Lys Gly Tyr His Leu Met Ser Phe Pro 1040 1045 1050 Gln Ser Ala Pro His Gly Val Val Phe Leu His Val Thr Tyr Val 1055 1060 1065 Pro Ala Gln Glu Lys Asn Phe Thr Thr Ala Pro Ala Ile Cys His 1070 1075 1080 Asp Gly Lys Ala His Phe Pro Arg Glu Gly Val Phe Val Ser Asn 1085 1090 1095 Gly Thr His Trp Phe Val Thr Gln Arg Asn Phe Tyr Glu Pro Gln 1100 1105 1110 Ile Ile Thr Thr Asp Asn Thr Phe Val Ser Gly Asn Cys Asp Val 1115 1120 1125 Val Ile Gly Ile Val Asn Asn Thr Val Tyr Asp Pro Leu Gln Pro 1130 1135 1140 Glu Leu Asp Ser Phe Lys Glu Glu Leu Asp Lys Tyr Phe Lys Asn 1145 1150 1155 His Thr Ser Pro Asp Val Asp Leu Gly Asp Ile Ser Gly Ile Asn 1160 1165 1170 Ala Ser Val Val Asn Ile Gln Lys Glu Ile Asp Arg Leu Asn Glu 1175 1180 1185 Val Ala Lys Asn Leu Asn Glu Ser Leu Ile Asp Leu Gln Glu Leu 1190 1195 1200 Gly Lys Tyr Glu Gln Tyr Ile Lys Trp Pro Trp Tyr Ile Trp Leu 1205 1210 1215 Gly Phe Ile Ala Gly Leu Ile Ala Ile Val Met Val Thr Ile Met 1220 1225 1230 Leu Cys Cys Met Thr Ser Cys Cys Ser Cys Leu Lys Gly Cys Cys 1235 1240 1245 Ser Cys Gly Ser Cys Cys Lys Phe Asp Glu Asp Asp Ser Glu Pro 1250 1255 1260 Val Leu Lys Gly Val Lys Leu His Tyr Thr 1265 1270 <210> 2 <211> 681 <212> PRT <213> Artificial sequence <220> <223> SARS-CoV-2 S protein S1 subunit His tag protein sequence <400> 2 Val Asn Leu Thr Thr Arg Thr Gln Leu Pro Pro Ala Tyr Thr Asn Ser 1 5 10 15 Phe Thr Arg Gly Val Tyr Tyr Pro Asp Lys Val Phe Arg Ser Ser Val 20 25 30 Leu His Ser Thr Gln Asp Leu Phe Leu Pro Phe Phe Ser Asn Val Thr 35 40 45 Trp Phe His Ala Ile His Val Ser Gly Thr Asn Gly Thr Lys Arg Phe 50 55 60 Asp Asn Pro Val Leu Pro Phe Asn Asp Gly Val Tyr Phe Ala Ser Thr 65 70 75 80 Glu Lys Ser Asn Ile Ile Arg Gly Trp Ile Phe Gly Thr Thr Leu Asp 85 90 95 Ser Lys Thr Gln Ser Leu Leu Ile Val Asn Asn Ala Thr Asn Val Val 100 105 110 Ile Lys Val Cys Glu Phe Gln Phe Cys Asn Asp Pro Phe Leu Gly Val 115 120 125 Tyr Tyr His Lys Asn Asn Lys Ser Trp Met Glu Ser Glu Phe Arg Val 130 135 140 Tyr Ser Ser Ala Asn Asn Cys Thr Phe Glu Tyr Val Ser Gln Pro Phe 145 150 155 160 Leu Met Asp Leu Glu Gly Lys Gln Gly Asn Phe Lys Asn Leu Arg Glu 165 170 175 Phe Val Phe Lys Asn Ile Asp Gly Tyr Phe Lys Ile Tyr Ser Lys His 180 185 190 Thr Pro Ile Asn Leu Val Arg Asp Leu Pro Gln Gly Phe Ser Ala Leu 195 200 205 Glu Pro Leu Val Asp Leu Pro Ile Gly Ile Asn Ile Thr Arg Phe Gln 210 215 220 Thr Leu Leu Ala Leu His Arg Ser Tyr Leu Thr Pro Gly Asp Ser Ser 225 230 235 240 Ser Gly Trp Thr Ala Gly Ala Ala Ala Tyr Tyr Val Gly Tyr Leu Gln 245 250 255 Pro Arg Thr Phe Leu Leu Lys Tyr Asn Glu Asn Gly Thr Ile Thr Asp 260 265 270 Ala Val Asp Cys Ala Leu Asp Pro Leu Ser Glu Thr Lys Cys Thr Leu 275 280 285 Lys Ser Phe Thr Val Glu Lys Gly Ile Tyr Gln Thr Ser Asn Phe Arg 290 295 300 Val Gln Pro Thr Glu Ser Ile Val Arg Phe Pro Asn Ile Thr Asn Leu 305 310 315 320 Cys Pro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala Ser Val Tyr 325 330 335 Ala Trp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr Ser Val 340 345 350 Leu Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly Val Ser 355 360 365 Pro Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala Asp Ser 370 375 380 Phe Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro Gly Gln Thr 385 390 395 400 Gly Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe Thr Gly 405 410 415 Cys Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys Val Gly Gly 420 425 430 Asn Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu Lys Pro 435 440 445 Phe Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser Thr Pro 450 455 460 Cys Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu Gln Ser Tyr 465 470 475 480 Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr Arg Val Val 485 490 495 Val Leu Ser Phe Glu Leu Leu His Ala Pro Ala Thr Val Cys Gly Pro 500 505 510 Lys Lys Ser Thr Asn Leu Val Lys Asn Lys Cys Val Asn Phe Asn Phe 515 520 525 Asn Gly Leu Thr Gly Thr Gly Val Leu Thr Glu Ser Asn Lys Lys Phe 530 535 540 Leu Pro Phe Gln Gln Phe Gly Arg Asp Ile Ala Asp Thr Thr Asp Ala 545 550 555 560 Val Arg Asp Pro Gln Thr Leu Glu Ile Leu Asp Ile Thr Pro Cys Ser 565 570 575 Phe Gly Gly Val Ser Val Ile Thr Pro Gly Thr Asn Thr Ser Asn Gln 580 585 590 Val Ala Val Leu Tyr Gln Asp Val Asn Cys Thr Glu Val Pro Val Ala 595 600 605 Ile His Ala Asp Gln Leu Thr Pro Thr Trp Arg Val Tyr Ser Thr Gly 610 615 620 Ser Asn Val Phe Gln Thr Arg Ala Gly Cys Leu Ile Gly Ala Glu His 625 630 635 640 Val Asn Asn Ser Tyr Glu Cys Asp Ile Pro Ile Gly Ala Gly Ile Cys 645 650 655 Ala Ser Tyr Gln Thr Gln Thr Asn Ser Pro Arg Arg Ala Arg Ala His 660 665 670 His His His His His His His His His 675 680 <210> 3 <211> 1216 <212> PRT <213> Artificial Sequence <220> <223> Full-length S protein His-tagged protein sequence of SARS-CoV-2 <400> 3 Val Asn Leu Thr Thr Arg Thr Gln Leu Pro Pro Ala Tyr Thr Asn Ser 1 5 10 15 Phe Thr Arg Gly Val Tyr Tyr Pro Asp Lys Val Phe Arg Ser Ser Val 20 25 30 Leu His Ser Thr Gln Asp Leu Phe Leu Pro Phe Phe Ser Asn Val Thr 35 40 45 Trp Phe His Ala Ile His Val Ser Gly Thr Asn Gly Thr Lys Arg Phe 50 55 60 Asp Asn Pro Val Leu Pro Phe Asn Asp Gly Val Tyr Phe Ala Ser Thr 65 70 75 80 Glu Lys Ser Asn Ile Ile Arg Gly Trp Ile Phe Gly Thr Thr Leu Asp 85 90 95 Ser Lys Thr Gln Ser Leu Leu Ile Val Asn Asn Ala Thr Asn Val Val 100 105 110[[ID=:31]] Ile Lys Val Cys Glu Phe Gln Phe Cys Asn Asp Pro Phe Leu Gly Val 115 120 125 Tyr Tyr His Lys Asn Asn Lys Ser Trp Met Glu Ser Glu Phe Arg Val 130 135 140 Tyr Ser Ser Ala Asn Asn Cys Thr Phe Glu Tyr Val Ser Gln Pro Phe 145 150 155 160 Leu Met Asp Leu Glu Gly Lys Gln Gly Asn Phe Lys Asn Leu Arg Glu 165 170 175 Phe Val Phe Lys Asn Ile Asp Gly Tyr Phe Lys Ile Tyr Ser Lys His 180 185 190 Thr Pro Ile Asn Leu Val Arg Asp Leu Pro Gln Gly Phe Ser Ala Leu 195 200 205 Glu Pro Leu Val Asp Leu Pro Ile Gly Ile Asn Ile Thr Arg Phe Gln 210 215 220 Thr Leu Leu Ala Leu His Arg Ser Tyr Leu Thr Pro Gly Asp Ser Ser 225 230 235 240 Ser Gly Trp Thr Ala Gly Ala Ala Ala Tyr Tyr Val Gly Tyr Leu Gln 245 250 255 Pro Arg Thr Phe Leu Leu Lys Tyr Asn Glu Asn Gly Thr Ile Thr Asp 260 265 270 Ala Val Asp Cys Ala Leu Asp Pro Leu Ser Glu Thr Lys Cys Thr Leu 275 280 285 Lys Ser Phe Thr Val Glu Lys Gly Ile Tyr Gln Thr Ser Asn Phe Arg 290 295 300 Val Gln Pro Thr Glu Ser Ile Val Arg Phe Pro Asn Ile Thr Asn Leu 305 310 315 320 Cys Pro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala Ser Val Tyr 325 330 335 Ala Trp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr Ser Val 340 345 350 Leu Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly Val Ser 355 360 365 Pro Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala Asp Ser 370 375 380 Phe Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro Gly Gln Thr 385 390 395 400 Gly Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe Thr Gly 405 410 415 Cys Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys Val Gly Gly 420 425 430 Asn Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu Lys Pro 435 440 445 Phe Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser Thr Pro 450 455 460 Cys Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu Gln Ser Tyr 465 470 475 480 Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr Arg Val Val 485 490 495 Val Leu Ser Phe Glu Leu Leu His Ala Pro Ala Thr Val Cys Gly Pro 500 505 510 Lys Lys Ser Thr Asn Leu Val Lys Asn Lys Cys Val Asn Phe Asn Phe 515 520 525 Asn Gly Leu Thr Gly Thr Gly Val Leu Thr Glu Ser Asn Lys Lys Phe 530 535 540 Leu Pro Phe Gln Gln Phe Gly Arg Asp Ile Ala Asp Thr Thr Asp Ala 545 550 555 560 Val Arg Asp Pro Gln Thr Leu Glu Ile Leu Asp Ile Thr Pro Cys Ser 565 570 575 Phe Gly Gly Val Ser Val Ile Thr Pro Gly Thr Asn Thr Ser Asn Gln 580 585 590 Val Ala Val Leu Tyr Gln Asp Val Asn Cys Thr Glu Val Pro Val Ala 595 600 605 Ile His Ala Asp Gln Leu Thr Pro Thr Trp Arg Val Tyr Ser Thr Gly 610 615 620 Ser Asn Val Phe Gln Thr Arg Ala Gly Cys Leu Ile Gly Ala Glu His 625 630 635 640 Val Asn Asn Ser Tyr Glu Cys Asp Ile Pro Ile Gly Ala Gly Ile Cys 645 650 655 Ala Ser Tyr Gln Thr Gln Thr Asn Ser Pro Arg Ala Ala Ala Ser Val 660 665 670 Ala Ser Gln Ser Ile Ile Ala Tyr Thr Met Ser Leu Gly Ala Glu Asn 675 680 685 Ser Val Ala Tyr Ser Asn Asn Ser Ile Ala Ile Pro Thr Asn Phe Thr 690 695 700 Ile Ser Val Thr Thr Glu Ile Leu Pro Val Ser Met Thr Lys Thr Ser 705 710 715 720 Val Asp Cys Thr Met Tyr Ile Cys Gly Asp Ser Thr Glu Cys Ser Asn 725 730 735 Leu Leu Leu Gln Tyr Gly Ser Phe Cys Thr Gln Leu Asn Arg Ala Leu 740 745 750 Thr Gly Ile Ala Val Glu Gln Asp Lys Asn Thr Gln Glu Val Phe Ala 755 760 765 Gln Val Lys Gln Ile Tyr Lys Thr Pro Pro Ile Lys Asp Phe Gly Gly 770 775 780 Phe Asn Phe Ser Gln Ile Leu Pro Asp Pro Ser Lys Pro Ser Lys Arg 785 790 795 800 Ser Phe Ile Glu Asp Leu Leu Phe Asn Lys Val Thr Leu Ala Asp Ala 805 810 815 Gly Phe Ile Lys Gln Tyr Gly Asp Cys Leu Gly Asp Ile Ala Ala Arg 820 825 830 Asp Leu Ile Cys Ala Gln Lys Phe Asn Gly Leu Thr Val Leu Pro Pro 835 840 845 Leu Leu Thr Asp Glu Met Ile Ala Gln Tyr Thr Ser Ala Leu Leu Ala 850 855 860 Gly Thr Ile Thr Ser Gly Trp Thr Phe Gly Ala Gly Ala Ala Leu Gln 865 870 875 880 Ile Pro Phe Ala Met Gln Met Ala Tyr Arg Phe Asn Gly Ile Gly Val 885 890 895 Thr Gln Asn Val Leu Tyr Glu Asn Gln Lys Leu Ile Ala Asn Gln Phe 900 905 910 Asn Ser Ala Ile Gly Lys Ile Gln Asp Ser Leu Ser Ser Thr Ala Ser 915 920 925 Ala Leu Gly Lys Leu Gln Asp Val Val Asn Gln Asn Ala Gln Ala Leu 930 935 940 Asn Thr Leu Val Lys Gln Leu Ser Ser Asn Phe Gly Ala Ile Ser Ser 945 950 955 960 Val Leu Asn Asp Ile Leu Ser Arg Leu Asp Lys Val Glu Ala Glu Val 965 970 975 Gln Ile Asp Arg Leu Ile Thr Gly Arg Leu Gln Ser Leu Gln Thr Tyr 980 985 990 Val Thr Gln Gln Leu Ile Arg Ala Ala Glu Ile Arg Ala Ser Ala Asn 995 1000 1005 Leu Ala Ala Thr Lys Met Ser Glu Cys Val Leu Gly Gln Ser Lys 1010 1015 1020 Arg Val Asp Phe Cys Gly Lys Gly Tyr His Leu Met Ser Phe Pro 1025 1030 1035 Gln Ser Ala Pro His Gly Val Val Phe Leu His Val Thr Tyr Val 1040 1045 1050 Pro Ala Gln Glu Lys Asn Phe Thr Thr Ala Pro Ala Ile Cys His 1055 1060 1065 Asp Gly Lys Ala His Phe Pro Arg Glu Gly Val Phe Val Ser Asn 1070 1075 1080 Gly Thr His Trp Phe Val Thr Gln Arg Asn Phe Tyr Glu Pro Gln 1085 1090 1095 Ile Ile Thr Thr Asp Asn Thr Phe Val Ser Gly Asn Cys Asp Val 1100 1105 1110 Val Ile Gly Ile Val Asn Asn Thr Val Tyr Asp Pro Leu Gln Pro 1115 1120 1125 Glu Leu Asp Ser Phe Lys Glu Glu Leu Asp Lys Tyr Phe Lys Asn 1130 1135 1140 His Thr Ser Pro Asp Val Asp Leu Gly Asp Ile Ser Gly Ile Asn 1145 1150 1155 Ala Ser Val Val Asn Ile Gln Lys Glu Ile Asp Arg Leu Asn Glu 1160 1165 1170 Val Ala Lys Asn Leu Asn Glu Ser Leu Ile Asp Leu Gln Glu Leu 1175 1180 1185 Gly Lys Tyr Glu Gln Tyr Ile Lys Trp Pro Gly Gly Gly Ser Gly 1190 1195 1200 Gly Gly Ser His His His His His His His His His His 1205 1210 1215 <210> 4 <211> 665 <212> PRT <213> Artificial Sequence <220> <223> His-tagged protein sequence of the S1 subunit of the SARS-CoV S protein <400> 4 Ser Asp Leu Asp Arg Cys Thr Thr Phe Asp Asp Val Gln Ala Pro Asn 1 5 10 15 Tyr Thr Gln His Thr Ser Ser Met Arg Gly Val Tyr Tyr Pro Asp Glu 20 25 30 Ile Phe Arg Ser Asp Thr Leu Tyr Leu Thr Gln Asp Leu Phe Leu Pro 35 40 45 Phe Tyr Ser Asn Val Thr Gly Phe His Thr Ile Asn His Thr Phe Asp 50 55 60 Asn Pro Val Ile Pro Phe Lys Asp Gly Ile Tyr Phe Ala Ala Thr Glu 65 70 75 80 Lys Ser Asn Val Val Arg Gly Trp Val Phe Gly Ser Thr Met Asn Asn 85 90 95 Lys Ser Gln Ser Val Ile Ile Ile Asn Asn Ser Thr Asn Val Val Ile 100 105 110 Arg Ala Cys Asn Phe Glu Leu Cys Asp Asn Pro Phe Phe Ala Val Ser 115 120 125 Lys Pro Met Gly Thr Gln Thr His Thr Met Ile Phe Asp Asn Ala Phe 130 135 140 Asn Cys Thr Phe Glu Tyr Ile Ser Asp Ala Phe Ser Leu Asp Val Ser 145 150 155 160 Glu Lys Ser Gly Asn Phe Lys His Leu Arg Glu Phe Val Phe Lys Asn 165 170 175 Lys Asp Gly Phe Leu Tyr Val Tyr Lys Gly Tyr Gln Pro Ile Asp Val 180 185 190 Val Arg Asp Leu Pro Ser Gly Phe Asn Thr Leu Lys Pro Ile Phe Lys 195 200 205 Leu Pro Leu Gly Ile Asn Ile Thr Asn Phe Arg Ala Ile Leu Thr Ala 210 215 220 Phe Ser Pro Ala Gln Asp Thr Trp Gly Thr Ser Ala Ala Ala Tyr Phe 225 230 235 240 Val Gly Tyr Leu Lys Pro Thr Thr Phe Met Leu Lys Tyr Asp Glu Asn 245 250 255 Gly Thr Ile Thr Asp Ala Val Asp Cys Ser Gln Asn Pro Leu Ala Glu 260 265 270 Leu Lys Cys Ser Val Lys Ser Phe Glu Ile Asp Lys Gly Ile Tyr Gln 275 280 285 Thr Ser Asn Phe Arg Val Val Pro Ser Gly Asp Val Val Arg Phe Pro 290 295 300 Asn Ile Thr Asn Leu Cys Pro Phe Gly Glu Val Phe Asn Ala Thr Lys 305 310 315 320 Phe Pro Ser Val Tyr Ala Trp Glu Arg Lys Lys Ile Ser Asn Cys Val 325 330 335 Ala Asp Tyr Ser Val Leu Tyr Asn Ser Thr Phe Phe Ser Thr Phe Lys 340 345 350 Cys Tyr Gly Val Ser Ala Thr Lys Leu Asn Asp Leu Cys Phe Ser Asn 355 360 365 Val Tyr Ala Asp Ser Phe Val Val Lys Gly Asp Asp Val Arg Gln Ile 370 375 380 Ala Pro Gly Gln Thr Gly Val Ile Ala Asp Tyr Asn Tyr Lys Leu Pro 385 390 395 400 Asp Asp Phe Met Gly Cys Val Leu Ala Trp Asn Thr Arg Asn Ile Asp 405 410 415 Ala Thr Ser Thr Gly Asn Tyr Asn Tyr Lys Tyr Arg Tyr Leu Arg His 420 425 430 Gly Lys Leu Arg Pro Phe Glu Arg Asp Ile Ser Asn Val Pro Phe Ser 435 440 445 Pro Asp Gly Lys Pro Cys Thr Pro Pro Ala Leu Asn Cys Tyr Trp Pro 450 455 460 Leu Asn Asp Tyr Gly Phe Tyr Thr Thr Thr Gly Ile Gly Tyr Gln Pro 465 470 475 480 Tyr Arg Val Val Val Leu Ser Phe Glu Leu Leu Asn Ala Pro Ala Thr 485 490 495 Val Cys Gly Pro Lys Leu Ser Thr Asp Leu Ile Lys Asn Gln Cys Val 500 505 510 Asn Phe Asn Phe Asn Gly Leu Thr Gly Thr Gly Val Leu Thr Pro Ser 515 520 525 Ser Lys Arg Phe Gln Pro Phe Gln Gln Phe Gly Arg Asp Val Ser Asp 530 535 540 Phe Thr Asp Ser Val Arg Asp Pro Lys Thr Ser Glu Ile Leu Asp Ile 545 550 555 560 Ser Pro Cys Ser Phe Gly Gly Val Ser Val Ile Thr Pro Gly Thr Asn 565 570 575 Ala Ser Ser Glu Val Ala Val Leu Tyr Gln Asp Val Asn Cys Thr Asp 580 585 590 Val Ser Thr Ala Ile His Ala Asp Gln Leu Thr Pro Ala Trp Arg Ile 595 600 605 Tyr Ser Thr Gly Asn Asn Val Phe Gln Thr Gln Ala Gly Cys Leu Ile 610 615 620 Gly Ala Glu His Val Asp Thr Ser Tyr Glu Cys Asp Ile Pro Ile Gly 625 630 635 640 Ala Gly Ile Cys Ala Ser Tyr His Thr Val Ser Leu Leu Arg Ala His 645 650 655 His His His His His His His His His 660 665 <210> 5 <211> 118 <212> PRT <213> Mouse <400> 5 Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Ser Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr Ser Gly 20 25 30 Tyr Tyr Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp 35 40 45 Met Gly Tyr Ile Ser Tyr Asp Asp Ser Asn Ser Tyr Asn Pro Ser Leu<� {50 55 60 Lys Asn Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe 65 70 75 80 Leu Lys Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Ala Arg Glu Gly Arg Gln Asn Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Leu Thr Val Ser Ser 115 <210> 6 <211> 116 <212> PRT <213> Mouse <400> 6 Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Ser Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr Ser Gly 20 25 30 Tyr Tyr Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp 35 40 45 Met Gly Tyr Ile Ser Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu 50 55 60 Lys Asn Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe 65 70 75 80 Leu Lys Leu Asn Ser Val Thr Ile Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Ala Arg Glu Gly Thr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu 100 105 110 Thr Val Ser Ser 115 <210> 7 <211> 118 <212> PRT <213> Mouse <400> 7 Asp Val Gln Leu Gln Glu Ser Gly Pro Ser Leu Val Arg Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Thr Gly Phe Ser Ile Asn Ser Asp 20 25 30 Cys Tyr Trp Ile Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Tyr 35 40 45 Ile Gly Tyr Thr Phe Tyr Ser Gly Ile Thr Tyr Tyr Asn Pro Ser Leu 50 55 60 Glu Ser Arg Thr Tyr Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Ser 65 70 75 80 Leu Lys Leu Ser Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Ala Arg Ile Thr Thr Arg Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser 115 <210> 8 <211> 120 <212> PRT <213> Mouse <400> 8 Glu Val Lys Phe Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Gly Val Ala Ser Gly Phe Thr Phe Asn Asn Tyr 20 25 30 Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Val Asp Trp Glu Glu Trp Tyr Phe Asp Val Trp Gly Thr 100 105 110 Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 9 <211> 118 <212> PRT <213> Mouse <400> 9 Glu Val Lys Ile Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Glu Ile Arg Asn Lys Ala Lys Asn His Ala Thr Asp Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser 115 <210> 10 <211> 119 <212> PRT <213> Mouse <400> 10 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Leu Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Gly Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr 85 90 95 Tyr Cys Thr Arg Arg Val Thr Ser Gly Gly Asp Tyr Trp Gly Arg Gly 100 105 110 Asn Ser Val Thr Val Ser Ser 115 <210> 11 <211> 119 <212> PRT <213> Mouse <400> 11 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Leu Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Ile Tyr Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Thr Tyr 85 90 95 Tyr Cys Ile Arg Arg Val Thr Ser Gly Gly Asp Tyr Trp Gly Arg Gly 100 105 110 Asn Ser Val Thr Val Ser Ser 115 <210> 12 <211> 119 <212> PRT <213> Mouse <400> 12 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Leu Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Asn 65 70 75 80 Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Ile Tyr 85 90 95 Tyr Cys Thr Arg Arg Val Thr Ser Gly Gly Asp Tyr Trp Gly Arg Gly 100 105 110 Asn Ser Val Thr Val Ser Ser 115 <210> 13 <211> 119 <212> PRT <213> Mouse <400> 13 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Leu Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu​​​​​​​Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Ile Tyr 85 90 95 Tyr Cys Thr Arg Arg Val Thr Ser Gly Gly Asp Tyr Trp Gly Arg Gly 100 105 110 Asn Ser Val Thr Val Ser Ser 115 <210> 14 <211> 119 <212> PRT <213> Mouse <400> 14 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Cys Ala Glu 50 55 60 Ser Val Lys Gly Ser Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 7� 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Arg Gly Leu Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Ser Val Thr Val Ser Ser 115 <210> 15 <211> 119 <212> PRT <213> Mouse <400> 15 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Glu Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Ser Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Arg Gly Leu Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Ser Val Thr Val Ser Ser 115 <210> 16 <211> 119 <212> PRT <213> Mouse <400> 16 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Arg Gln Leu Thr Gly Thr Arg Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Thr Leu Thr Val Ser Ser 115 <210> 17 <211> 119 <212> PRT <213> Mouse <400> 17 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Ala 35 40 45 Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Ser His Leu Ser Gly Ile Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Thr Leu Thr Val Ser Ser 115 <210> 18 <211> 118 <212> PRT <213> Mouse <400> 18 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Ile 35 40 45 Thr Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Lys Gly Leu Ser Phe Met Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser 115 <210> 19 <211> 120 <212> PRT <213> Mouse <400> 19 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Ala Met Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Ser Lys Leu Thr Gly Pro Asn Phe Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Thr Leu Thr Val Ser Ser 115 120 <210> 20 <21l> 118 <212> PRT <213> Mouse <400> 20 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 It should be noted that there seems to be a misspelling in the tag where it says "<21l> 118" instead of "<211> 118". This has been left as is in the translation according to the instructions.Ala Glu Ile Arg Asn Lys Ala His Asn His Ala Thr Asp Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser 115 <210> 21 <211> 118 <212> PRT <213> Mouse <400> 21 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Glu Ile Arg Asn Lys Ala Lys Asn His Ala Thr Asp Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser 115 <210> 22 <211> 118 <212> PRT <213> Mouse <400> 22 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Glu Ile Arg Asn Lys Ala Lys Asn Gln Ala Thr Asn Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Ile Trp Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser 115 <210> 23 <211> 118 <212> PRT <213> Mouse <400> 23 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Glu Ile Arg Asn Lys Ala Asn Asn His Ala Thr Asp Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser 115 <210> 24 <211> 118 <212> PRT <213> Mouse <400> 24 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45[[ID=)29]] Ala Glu Ile Arg Asn Lys Ala Tyr Asn His Ala Thr Tyr Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Arg Pro Asn Trp Asp Val Val Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Leu Thr Val Ser Ser 115 <210> 25 <211> 118 <212> PRT <213> Mouse <400> 25 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Glu Ile Arg Asn Lys Ala Tyr Thr His Ala Thr Tyr Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Arg Pro Asn Trp Asp Val Val Asp Trp Gly Gln Gly Thr 100 105 110 Thr Leu Thr Val Ser Ser 115 <210> 26 <211> 118 <212> PRT <213> Mouse <400> 26 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Glu Ile Arg Asn Lys Gly Lys Asn Tyr Ala Thr Asp Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser 115 <210> 27 <~211> 118 <212> PRT <213> Mouse <400> 27 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Note: There seems to be a potential error in the original text where <211> has a tilde (~) in the translation. It should be just <211> as in the original. Please check if this is correct in the source material.Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Glu Met Arg Asn Lys Ala Asn Asn His Ala Thr Asp Tyr Gly Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser 115 <210> 28 <211> 119 <212> PRT <213> Mouse <400> 28 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Lys Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Pro Leu Ser Asn Tyr Ala Met Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Ser Val Thr Val Ser Ser 115 <210> 29 <211> 119 <212> PRT <213> Mouse <400> 29 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Lys Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Pro Leu Ser Asn Tyr Ala Met Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Ser Val Thr Val Ser Ser 115 <210> 30 <211> 119 <212> PRT <213> Mouse <400> 30 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45[[ID=四十一]] [[ID=四十二]]Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu[[ID=四十三]] [[ID=四十四]]50 55 60[[ID=四十五]] Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Gly 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Ser His Leu Thr Gly Ile Phe Asp Tyr Trp Gly Gln Ala 100 105 110 Thr Thr Leu Thr Val Ser Ser 115 <210> 31 <211> 119 <212> PRT <213> Mouse <400> 31 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Ser Ser His Leu Thr Gly Ile Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Thr Leu Thr Val Ser Ser 115 <210> 32 <211> 119 <212> PRT <213> Mouse <400> 32 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Ser His Leu Thr Gly Ile Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Thr Leu Thr Val Ser Ser 115 <210> 33 <211> 119 <212> PRT <213> Mouse <400> 33 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu[[ID=三十一]] [[ID=三十二]]50 55 60[[ID=三十三]] [[ID=三十四]]Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser[[ID=三十五]] [[ID=三十六]]65 70 75 80[[ID=三十七]] [[ID=三十八]]Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr[[ID=三十九]] [[ID=四十]]85 90 95[[ID=四十一]] [[ID=四十二]]Tyr Cys Thr Ser His Leu Thr Trp Ile Phe Asp Tyr Trp Gly Gln Gly[[ID=四十三]] [[ID=四十四]]100 105 110[[ID=四十五]] [[ID=四十六]]Thr Thr Leu Thr Val Ser Ser[[ID=四十七]] [[ID=四十八]]115 <210> 34 <211> 119 <212> PRT <213> Mouse <400> 34 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Tyr Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Phe Cys Thr Arg Gly Ile Thr Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Thr Leu Thr Val Ser Ser 115 <210> 35 <211> 119 <212> PRT <213> Mouse <400> 35 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu 50 55 60 Ser Val Asn Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Arg Gly Ile Thr Tyr Phe Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Thr Leu Thr Val Ser Ser 115 <210> 36 <211> 118 <212> PRT <213> Mouse <400> 36 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Thr Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Arg Leu Gly Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 37 <211> 119 <212> PRT <213> Mouse <400> 37 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Val Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Ser His Leu Thr Gly Ile Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Thr Leu Thr Val Ser Ser 115 <210> 38 <211> 119 <212> PRT <213> Mouse <400> 38 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Asn Lys Ala Asn Asn His Val Thr Tyr Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Gly Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Arg Gly Leu Ser Tyr Thr Met Asp Ser Trp Gly Gln Gly 100 105 110 Thr Ser Val Thr Val Ser Ser 115 <210> 39 <211> 119 <212> PRT <213> Mouse <400> 39 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Thr Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Arg Gln Leu Ala Gly Thr Arg Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Thr Leu Thr Val Ser Ser 115 <210> 40 <211> 118 <212> PRT <213> Mouse <400> 40 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Ile Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Glu Ile Arg Asn Lys Ala Asn Asn His Ala Thr Asp Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser 115 <210> 41 <211> 118 <212> PRT <213> Mouse <400> 41 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Ala Trp Val 35 40 45 Ala His Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Gly His Pro Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser 115 <210> 42 <211> 118 <212> PRT <213> Mouse <400> 42 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala His Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu 50 �5 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Gly His Pro Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser 115 <210> 43 <211> 119 <212> PRT <213> Mouse <400> 43 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Val Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Ala Ile Ser Arg Asp Asp Ser Lys Arg Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Thr Tyr 85 90 95 Tyr Cys Ile Arg Gly Leu Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Ser Val Thr Val Ser Ser 115 <210> 44 <211> 118 <212> PRT <213> Mouse <400> 44 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Tyr Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Glu Ile Arg Asn Lys Ala Lys Asn His Ala Thr Asp Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser 115 <210> 45 <211> 118 <212> PRT <213> Mouse <400> 45 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Val Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Glu Met Arg Asn Lys Ala Asn Asn His Ala Thr Asp Tyr Gly Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser 115 <210> 46 <211> 118 <212> PRT <213> Mouse <400> 46 Glu Val Lys Leu Val Glu Ser Glu Gly Gly Leu Val Gln Pro Gly Ser 1 5 10 15 Ser Met Lys Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Tyr Met Ala Trp Val Arg Gln Val Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Asn Ile Asn Tyr Asp Gly Ile Ser Thr Phe Tyr Leu Asp Ser Leu 50 55 60 Lys Ser Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ile Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Ala Arg Glu Gly Ala Ala Gln Ala Leu Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Leu Thr Val Ser Ser 115 <210> 47 <211> 118 <212> PRT <213> mice <400> 47 Glu Val Lys Leu Val Glu Ser Glu Gly Gly Leu Val Gln Pro Gly Ser 1 5 10 15 Ser Met Lys Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Tyr Met Ala Trp Val Arg Gln Val Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Asn Ile Asn Tyr Asp Gly Ser Ser Ile Tyr Tyr Leu Asp Ser Leu 50 55 60 Lys Ser Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ile Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Ala Arg Glu Gly Ala Ala Gln Ala Leu Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Leu Thr Val Ser Ser 115 <210> 48 <211> 119 <212> PRT <213> Mouse <400> 48 Glu Val Lys Pro Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Ala Ser His Leu Thr Gly Ile Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Thr Leu Thr Val Ser Ser 115 <210> 49 <211> 118 <212> PRT <213> Mouse <400> 49 Glu Val Lys Val Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Ser Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Arg Leu Gly Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 50 <211> 118 <212> PRT <213> Mouse <400> 50 Glu Val Lys Val Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Arg Leu Gly Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 51 <211> 119 <212> PRT <213> Mouse <400> 51 Glu Val Lys Val Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Glu Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu 50 55 60 [[ID=~33]] Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Gly Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Arg Gly Leu Ser Tyr Thr Met Asp Tyr Trp Gly Gln Gly 100~105 110 Thr Ser Val Thr Val Ser Ser 115 <210> 52 <211> 119 <212> PRT <213> Mouse <400> 52 Glu Val Lys Val Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Arg Gly Ile Thr Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Thr Leu Thr Val Ser Ser 115 <210> 53 <211> 118 <212> PRT <213> Mouse <400> 53 Glu Val Lys Val Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala His Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Gly His Pro Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser 115 <210> 54 <211> 118 <212> PRT <213> Mouse <400> 54 Glu Val Asn Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Glu Ile Arg Asn Lys Ala Lys Asn His Ala Thr Asp Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser 115 <210> 55 <211> 118 <212> PRT <213> Mouse <400> 55 Glu Val Asn Leu Glu Glu Ser Gly Gly Val Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Glu Ile Arg Asn Lys Ala Lys Asn His Ala Thr Asp Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser 115 <210> 56 <211> 120 <212> PRT <213> Mouse <400> 56 Glu Val Gln Leu Leu Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Tyr Ile Lys Asp Asp 20 25 30 Ser Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Asp Pro Glu Ser Gly Asp Thr Glu Tyr Ala Ser Lys Phe 50 55 60 Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Thr Leu Pro Leu Tyr Tyr Asp Tyr Val Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 57 <211> 120 <212> PRT <213> Mouse <400> 57 Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Glu Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp 20 25 30 Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Glu Pro Asp Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe 50 55 60 Gln Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Thr Leu Ile Tyr Tyr Tyr Gly Ser Ala Ser Asp Tyr Trp Gly Gln 100, 105, 110 Gly Thr Thr Leu Thr Val Ser Ser 115 120 <210> 58 <211> 120 <212> PRT <213> Mouse <400> 58 Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp 20 25 30 Tyr Ile His Trp Met Lys Leu Arg Pro Glu Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Asp Pro Glu Lys Ala Val Thr Glu Tyr Ala Ser Arg Phe 50 55 60 Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Leu Gln Leu Asn Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Thr Leu Pro Leu Tyr Tyr Asp Tyr Pro Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 59 <211> 121 <212> PRT <213> Mouse <400> 59 Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp 20 25 30 Tyr Ile His Trp Val Lys Gln Arg Pro Asp Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe 50 55 60 Gln Gly Lys Ala Thr Ile Thr Ala Asp Ala Ser Ser Asn Thr Ala Tyr 65 70 75 80 Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Asn Phe Gly Ser Ser Gln Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 60 <211> 121 <212> PRT <213> Mouse <400> 60 Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp 20 25 30 Tyr Ile His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe 50 55 60 Gln Asp Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr His Tyr Gly Ser Ser Tyr Ala Phe Tyr Ala Leu Asp Cys Trp Gly 100 105 110 Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 61 <211> 121 <212> PRT <213> Mouse <400> 61 Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp 20 25 30 Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 35 40 45 Gly Gly Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe 50 55 60 Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Asn Tyr Gly Ser Ser Gln Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 62 <211> 120 <212> PRT <213> Mouse <400> 62 Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp 20 25 30 Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Asp Pro Asp Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe 50 55 60 Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Leu Gln Leu Ser Ser Leu Thr Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Thr Leu Ile Tyr Tyr Tyr Gly Ser Cys Ser Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Thr Leu Thr Val Ser Ser 115 120 <210> 63 <211> 119 <212> PRT <213> Mouse <400> 63 Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp 20 25 30 Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe 50 55 60 Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Leu Leu Leu Ser Ser Leu Thr Ser Ala Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Gly Asp Ser Asn Tyr Arg Tyr Ala Leu Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Ser Val Thr Val Ser Ser 115 <210> 64 <211> 120 <212> PRT <213> Mouse <400> 64 Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp 20 25 30 Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe 50 55 60 Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Asn Leu Ile Tyr Tyr Tyr Gly Ser Ser Pro Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Thr Leu Thr Val Ser Ser 115 120 <210> 65 <211> 121 <212> PRT <213> Mouse <400> 65 Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp 20 25 30 Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe 50 55 60 Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Thr Trp Gly Tyr Thr Asn Tyr Val Glu Ala Met Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 66 <211> 121 <212> PRT <213> Mouse <400> 66 Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp 20 25 30 Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe 50 55 60 Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Thr Tyr Gly Ser Ser Tyr Val Tyr Tyr Ala Met Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 67 <211> 120 <212> PRT <213> Mouse <400> 67 Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp 20 25 30 Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe 50 55 60 Gln Gly Lys Ala Thr Ile Thr Thr Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Asn Leu Leu Tyr Tyr Tyr Asp Ser Ser Tyr Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Thr Leu Thr Val Ser Ser 115 120 <210> 68 <211> 119 <212> PRT <213> Mouse <400> 68 Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp 20 25 30 Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe 50 55 60 Gln Gly Lys Ser Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Gly Asp Ser Asn Tyr Arg Tyr Ala Leu Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Ser Val Thr Val Ser Ser 115 <210> 69 <211> 120 <212> PRT <213> Mouse <400> 69 Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp 20 25 30 Tyr Met Asn Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe 50 55 60 Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Thr Leu Ile Tyr Tyr Tyr Gly Ser Cys Pro Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Thr Leu Thr Val Ser Ser 115 120 <210> 70 <211> 120 <212> PRT <213> Mouse <400> 70 Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Tyr Ile Lys Asp Asp 20 25 30 Tyr Leu His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Asp Pro Glu Asn Gly Asp Ala Glu Tyr Ala Ser Lys Phe 50 55 60 Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Thr Leu Ile Tyr Tyr Tyr Gly Ser Asn Ser Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Thr Leu Thr Val Ser Ser 115 120 <210> 71 <211> 121 <212> PRT 9><213> Mouse <400> 71 Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Thr Val Ser Gly Phe Asn Ile Lys Asp Asp 20 25 30 Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe 50 55 60 Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Asn Ser Gly Ser Ser Gln Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 72 <211> 114 <212> PRT <213> Mouse <400> 72 Glu Val Gln Leu Gln Gln Ser Gly Pro Asp Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 20 25 30 Ser Met Asn Trp Val Lys Gln Ser Pro Glu Lys Ser Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn Pro Asn Thr Gly Asp Thr Thr Tyr Asn Gln Arg Phe 50 55 60 Lys Ala Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Ala Gly Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ala <210> 73 <211> 117 <212> PRT <213> Mouse <400> 73 Glu Val Gln Leu Gln Gln Ser Gly Pro Asp Leu Val Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30[[ID=^]] Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ile Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Trp Asp His Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 74 <211> 117 <212> PRT <213> Mouse <400> 74 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Leu Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Met Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Trp Asp Asn Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 75 <211> 114 <212> PRT <213> Mouse <400> 75 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Met Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 20 25 30 Ser Met Asn Trp Val Lys Gln Ser Pro Glu Lys Ser Leu Glu Trp Leu 35 40 45 Gly Glu Ile Asn Pro Ser Thr Gly Gly Thr Thr Tyr Asn Gln His Phe 50 55 60 Lys Ala Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Ala Gly Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ala <210> 76 <211> 117 <212> PRT <213> Mouse <400> 76 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Phe Thr Phe Thr Asp Tyr 20 25 30 Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ile Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Trp Asp Asn Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 77 <211> 117 <212> PRT <213> Mouse <400> 77 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Asn Met Asp Trp Val Lys Gln Ser His Gly Glu Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Val Phe Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Trp Asp Asn Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 78 <211> 117 <212> PRT <213> Mouse <400> 78 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Asp Asn Gly Gly Thr Ile Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Trp Asp Asn Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 79 <211> 117 <212> PRT <213> Mouse <400> 79 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Lys Asn Gly Gly Thr Val Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Gly Leu Thr Ser Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95 Ala Arg Asp Gly Ser Lys Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 80 <211> 117 <212> PRT <213> Mouse <400> 80 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr ]>20 25 30 Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Asn Asn Gly Gly Ile Ile Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Trp Asp Asn Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 81 <211> 117 <212> PRT <213> Mouse <400> 81 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ile Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Ser Lys Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 82 <211> 117 <212> PRT <213> Mouse <400> 82 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ile Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Trp Asp Asn Ala Met Asp Tyr Trp Gly Pro Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 83 <211> 117 <212> PRT <213> Mouse <400> 83 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ile Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Trp Asp Asn Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 84 <211> 117 <212> PRT <213> Mouse <400> 84 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ile Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 7​​​​​​​​​​​​​​​​​​​​ <400> 85 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Thr Asn Gly Gly Thr Val Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Trp Asp Asn Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 86 <211> 117 <212> PRT <213> Mouse <400> 86 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Asn Met Asp Trp Val Lys Gln Ser His Gly Met Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Val Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Asp Trp Asp Asn Ala Met Asp Tyr Trp Gly Pro Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 87 <211> 121 <212> PRT <213> Mouse <400> 87 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Asp Thr Phe Thr Asp Tyr 20 25 30 Tyr Ile Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Gly Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Met Asp Tyr Tyr Asp Leu His Trp Tyr Phe Asp Val Trp Gly 100 105 110 Thr Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 88 <211> 121 <212> PRT <213> Mouse <400> 88 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly His Thr Phe Thr Asp Tyr 20 25 30 Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Lys Asn Gly Gly Asn Ser Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Met Asp Tyr Tyr Asp Leu His Trp Tyr Phe Asp Val Trp Gly 100 105 110 Ser Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 89 <211> 114 <212> PRT <213> Mouse <400> 89 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 20 25 30 Gln Met Asn Trp Val Lys Gln Ser Pro Glu Lys Ser Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn Pro Arg Thr Gly Gly Thr Thr Tyr Asn Gln Lys Phe 50 55 60 Lys Ala Lys Ala Thr Leu Thr Val Asp Ile Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Ala Gly Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ala <210> 90 <211> 114 <212> PRT <213> Mouse <400> 90 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 20 25 30 Ser Met Asn Trp Val Lys Gln Ser Pro Glu Lys Ser Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn Pro Ser Thr Gly Gly Thr Thr Tyr Asn Gln Lys Phe 50 55 60 Lys Ala Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Ile Gln Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Ala Gly Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ala <210> 91 <211> 114 <212> PRT <213> Mouse <400> 91 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 20 25 30 Ser Met Asn Trp Val Lys Gln Ser Pro Glu Lys Ser Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn Pro Ser Thr Gly Gly Thr Thr Tyr Asn Gln Lys Phe 50 55 60 Lys Ala Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Ala Gly Thr Tyr Trp Gly Gln Gly Thr Le Thr Leu Val Thr Val 100 105 110 Phe Ala <210> 92 <211> 114 <212> PRT <213> Mouse <400> 92 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 20 25 30 Ser Met Asn Trp Val Lys Gln Ser Pro Glu Lys Ser Leu Glu Trp Ile<000·2772>35 40 45 Gly Glu Ile Asn Pro Ser Thr Gly Thr Thr Thr Tyr Asn Gln Lys Phe 50 55 60 Lys Ala Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 ]]Ala Arg Gly Ala Gly Ser Tyr Trp Gly Gln Gly Thr Leu Val Thr Val 100 105 110 Ser Ala <210> 93 <211> 114 <212> PRT <213> Mouse <400> 93 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 1'5 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 20 25 30 Tyr Met Asn Trp Val Lys Gln Ser Pro Glu Lys Ser Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn Pro Ser Thr Gly Gly Thr Thr Tyr Asn Gln Lys Phe 50 55 60 Lys Ala Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Arg Ala Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 100 105 110 Ser Ser <210> 94 <211> 116 <212> PRT <213> Mouse <400> 94 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Cys 20 25 30 Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Asn Thr Gly Gly Thr Thr Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Ala Asn Trp Val Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ala 115 <210> 95 <211> 116 <212> PRT <213> Mouse <400> 95 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ser 20 25 30 Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Ala Asn Trp Val Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ala 115 <210> 96 <211> 121 <212> PRT <213> Mouse <400> 96 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Gly Tyr Lys Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Met Asp Tyr Tyr Asp Leu His Trp Tyr Phe Asp Val Trp Gly 100 105 110 Thr Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 97 <211> 118 <212> PRT <213> Mouse <400> 97 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Arg Thr Ala Tyr 65 70 75 80 Met Glu Phe Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Gly Ile Tyr Gly Tyr Phe Asp Val Trp Gly Thr Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 98 <211> 118 <212> PRT <213> Mouse <400> 98 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Arg Glu Gly Thr Tyr Gly Tyr Phe Asp Val Trp Gly Thr Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 99 <211> 118 <212> PRT <213> Mouse <400> 99 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Gly Ile Tyr Gly Tyr Phe Asp Val Trp Gly Thr Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 100 <211> 116 <212> PRT <213> Mouse <400> 100 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Arg Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Thr Arg His Gly Thr Arg Gly Asp Tyr Trp Gly Gln Gly Thr Thr Leu 100 105 110 Thr Val Ser Ser 115 <210> 101 <211> 120 <212> PRT <213> Mouse <400> 101 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 [[ID=4 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Gly Thr Ala Tyr 65 70 75 80 Met Asp Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Ser Cys 85 90 95 Ala Arg Ser Tyr Tyr Gly Ser Gln Tyr Gln Leu Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Thr Leu Thr Val Ser Ser 115 120 <210> 102 <211> 121 <212> PRT <213> Mouse <400> 102 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Tyr Tyr Phe Ala Leu Tyr Tyr Ser Ala Met Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 103 <211> 121 <212> PRT <213> Mouse <400> 103 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Tyr Tyr Tyr Ala Leu Tyr Tyr Ser Ala Met Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 104 <211> 120 <212> PRT <213> Mouse <400> 104 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe 50 55 60 Arg Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Tyr Gly Ser Pro Trp Gly Phe Phe Asp Val Trp Gly Thr 100 105 110 Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 105 <211> 114 <212> PRT <213> Mouse <400> 105 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Asn Met His Trp Val Lys Gln Ser His Ala Lys Ser Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Asp Pro Asn Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asn Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Val Asn Ser Asn Trp Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val 100 105 110 Ser Ser <210> 106 <211> 114 <212> PRT <213> Mouse <400> 106 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Asn Pro Asp Asn Gly Asp Thr Thr Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asn Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Val Asn Ser Asn Trp Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val 100 105 110 Ser Ser <210> 107 <211> 114 <212> PRT <213> Mouse <400> 107 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Asn Pro Asp Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Ala Leu Thr Ile Asn Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Val Asn Ser Asn Trp Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val 100 105 110 Ser Ser <210> 108 <211> 114 <212> PRT <213> Mouse <400> 108 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Asn Pro Asp Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asn Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Val Asn Ser Asn Trp Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val 100 105 110 Ser Ser <210> 109 <211> 114 <212> PRT <213> Mouse <400> 109 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Asn Pro Asn Asp Gly Gly Thr Asn Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asn Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Val Asn Ser Asn Trp Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val 100 105 110 Ser Ser <210> 110 <211> 114 <212> PRT <213> Mouse <400> 110 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asn Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Val Asn Ser Asn Trp Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val 100 105 110 Ser Ser <210> 111 <211> 114 <212> PRT <213> Mouse <400> 111 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Val 35 40 45 Gly Tyr Ile Asn Pro Asp Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asn Lys Ser Ser Ser Thr Ala Tyr 65 70 �5 80 Met Glu Leu Arg Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Val Asn Ser Asn Trp Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val 100 105 110 Ser Ser[[ID=۳6]] <210> 112 <211> 114 <212> PRT <213> Mouse <400> 112 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Asn Met His Trp Val Lys Gln Ser Pro Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Asn Pro Asp Asn Gly Gly Pro Asn Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Met Ala Thr Leu Thr Val Asn Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Val Asn Ser Asn Trp Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val 100 105 110 Ser Ser <210> 113 <211> 121 <212> PRT <213> Mouse <400> 113 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Arg Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Met Asn Trp Met Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Gly Tyr Asn Gln Lys Phe 50 55 60 Arg Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Met Asp Tyr Tyr Asp Leu Gln Trp Tyr Phe Asp Val Trp Gly 100 105 110 Thr Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 114 <211> 118 <212> PRT <213> Mouse <400> 114 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Arg Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Pro Asn Asn Gly Gly Asn Gly Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Ala Gly Pro Pro Trp Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ala 115 <210> 115 <211> 120 <212> PRT <213> Mouse <400> 115 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Thr 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Met Asn Trp Val Lys Gln Arg His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Asn Asn Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Tyr Gly Ser Gly Trp Gly Phe Phe Asp Val Trp Gly Thr 100 105 110 Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 116 <211> 116 <212> PRT <213> Mouse <400> 116 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Val Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Arg Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg His Gly Thr Arg Gly Asp Tyr Trp Gly Gln Gly Thr Thr Leu 100 105 110 Thr Val Ser Ser 115 <210> 117 <211> 117 <212> PRT <213> Mouse <400> 117 Glu Val Gln Leu Gln Gln Ser Gly Pro Val Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Val Ile Asn Pro Tyr Asn Gly Gly Ala Ser Tyr Ser Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Arg Leu Ala Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr 100 105 110 Leu Thr Val Ser Ser 115 <210> 118 <211> 121 <212> PRT <213> Mouse <400> 118 Glu Val Gln Leu Gln Gln Ser Arg Ala Glu Phe Val Arg Pro Gly Ala 1 5 10 15 Ser Val Met Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp 20 25 30 Asn Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Ala Tyr Ala Ser Lys Phe 50 55 60 Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80<S Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Asn Phe Gly Ser Ser Gln Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly 100 105 110<S Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 119 <211> 119 <212> PRT <213> Mouse <400> 119 Glu Val Gln Leu Gln Gln Ser Val Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Thr Pro Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Met His Trp Val Gln Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Ala Asn Gly Tyr Ala Lys Tyr Ala Pro Lys Phe 50 55 60 Gln Gly Lys Ala Thr Ile Ser Ala Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Ile Tyr Tyr Cys 85 90 95 Ala Asp Ile Tyr Pro Tyr Val Ile Gly Phe Ser Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ala 115 <210> 120 <211> 122 <212> PRT <213> Mouse <400> 120 Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Gly Leu His Trp Val Arg Gln Ala Pro Glu Asn Gly Leu Glu Trp Val 35 40 45 Ala Tyr Ile Ser Ser Gly Ser Ser Thr Ile Tyr Tyr Ala Asp Thr Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Phe 65 70 75 80 Leu Gln Met Thr Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr Cys 85 90 95 Ala Arg Arg Leu Tyr Asp Tyr Asp Val Ser Tyr Ala Met Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 121 <211> 122 <212> PRT <213> Mouse <400> 121 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Tyr Ile Ser Ser Gly Ser Ser Thr Ile Tyr Tyr Ala Asp Thr Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Phe 65 70 75 80 Leu Gln Met Thr Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Arg Val Tyr Asp Phe Asp Val Ser Tyr Ala Met Asp Tyr Trp 100 105 110 Gly Arg Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 122 <211> 119 <212> PRT <213> Mouse <400> 122 Glu Val Gln Pro Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Arg Gly Leu Ser Tyr Thr Met Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Ser Val Thr Val Ser Ser 115 <210> 123 <211> 120 <212> PRT <213> Mouse <400> 123 Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Ser Ile His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu Trp Ile 35 40 45 Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe 50 55 60 Thr Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Arg Asp Gly Tyr Pro Arg Tyr Tyr Ala Leu Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 124 <211> 120 <212> PRT <213> Mouse <400> 124 Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Ser Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu Trp Ile 35 40 45 Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn His Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ser Val Tyr Phe Cys 85 90 95 Ala Arg Asp Gly Tyr Pro Arg Tyr Tyr Ala Leu Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 125 <211> 116 <212> PRT <213> Mouse <400> 125 Gln Gly Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Thr Gly Tyr Arg Phe Thr Gly Tyr 20 25 30 Trp Ile Glu Trp Ile Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Leu Pro Gly Ser Gly Ser Thr Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Gly Lys Ala Thr Phe Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Thr Glu Asp Ser Ala Ile Tyr Tyr Cys 85 90 95 Ala Ser Ser Gly Thr Asp Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu 100 105 110 Thr Val Ser Ser 115 <210> 126 <211> 120 <212> PRT <213> Mouse <400> 126 Gln Gly Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Trp Ile Val Trp Ala Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Tyr Pro Gly Gly Gly Tyr Thr Asn Tyr Asn Glu Asn Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Phe Ser Ser Leu Thr Ser Glu Asp Ser Ala Ile Tyr Tyr Cys 85 90 95 Ala Arg Ser Lys Gly Leu Thr Gly Thr Leu Phe Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Thr Leu Thr Val Ser Ser 115 120 <210> 127 <211> 118 <212> PRT <213> Mouse <400> 127 Gln Ile Gln Phe Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Val Tyr Thr Phe Thr Glu Tyr 20 25 30 Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met 35 40 45 Gly Trp Ile His Thr Tyr Ser Gly Glu Pro Thr Tyr Ala Asp Asp Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Ala Arg Trp Arg Phe Tyr Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 128 <211> 122 <212> PRT <213> Mouse <400> 128 Gln Ile Gln Leu Val Gln Ser Gly Pro Asp Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr 20 25 30 Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met 35 40 45 Gly Leu Ile Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Pro Tyr Phe Cys 85 90 95 Val Arg Gly Gly Tyr Gly Asn Tyr Val Arg Trp Tyr Phe Asp Val Trp 100 105 110 Gly Thr Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 129 <211> 118 <212> PRT <213> Mouse <400> 129 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Gly Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 35 40 45 Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Gly Arg Asp Asp Asp Tyr Asp Gly Phe Ala Tyr Trp Gly Gln Gly Thr 100 1 "105 110 Leu Val Thr Val Ser Ala 115 <210> 130 <211> 122 <212> PRT <213> Mouse <400> 130 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Glu Tyr Thr Leu Thr Glu Tyr 20 25 30 Leu Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met 35 40 45 Gly Met Ile Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Val Arg Gly Gly Tyr Gly Asn Tyr Val Arg Trp Tyr Phe Asp Val Trp 100 105 110 Gly Thr Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 131 <211> 118 <212> PRT <213> Mouse <400> 131 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Thr Tyr 20 25 30 Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 35 40 45 Gly Trp Ile Asn Thr Tyr Ala Gly Val Pro Thr Tyr Ala Asp Asp Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Lys Tyr Phe Cys 85 90 95 Thr Arg Asp Asp Asp Tyr Asp Gly Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ala 115 <210> 132 <211> 114 <212> PRT <213> Mouse <400> 132 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met 35 40 45 Gly Met Ile Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Val Arg Ser Gly Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 100 105 110 Ser Ser <210> 133 <211> 113 <212> PRT <213> Mouse <400> 133 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr 20 25 30 Ala Met His Gly Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met 35 40 45 Gly Met Ile Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Val Asn Ser Asn Leu Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser 100 105 110 Ser <210> 134 <211> 122 <212> PRT <213> Mouse <400> 134 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr 20 25 30 Leu Met His Trp Val Lys Gln Ala Pro Gly Lys Asp Phe Lys Trp Met 35 40 45 Gly Met Thr Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe 50 55 60 ​​​​​​​​​​​​​​​​<210> 135 <211> 122 <212> PRT <213> Mouse <400> 135 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr 20 25 30 Leu Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met 35 40 45 Gly Met Ile Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Leu Cys 85 90 95 Val Arg Gly Gly Tyr Gly Asn Tyr Val Arg Trp Tyr Phe Asp Val Trp 100 105 110 Gly Thr Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 136 <211> 116 <212> PRT <213> Mouse <400> 136 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr 20 25 30 Pro Met His Trp Met Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met 35 40 45 Gly Met Ile Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Arg Asp Tyr Gly Gly Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val 100 105 110 Thr Val Ser Ser 115 <210> 137 <211> 122 <212> PRT <213> Mouse <400> 137 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr 20 25 30 Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Asp Phe Lys Trp Met 35 40 45 Gly Met Thr Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Asp Ser 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Thr Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Val Arg Gly Gly Tyr Gly Asn Tyr Val Arg Trp Tyr Phe Asp Val Trp 100 105 110 Gly Thr Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 138 <211> 118 <212> PRT <213> Mouse <400> 138 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr 20 25 30 Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met 35 40 45 Gly Leu Ile Tyr Ser Asp Thr Gly Glu Pro Thr His Ala Glu Glu Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Val Arg Gly Glu Asn Trp Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Leu Thr Val Ser Ser 115 <210> 139 <211> 118 <212> PRT <213> Mouse <400> 139 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr 20 25 30 Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met 35 40 45 Gly Leu Ile Tyr Thr Asp Thr Gly Asp Pro Thr Tyr Ala Glu Glu Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ser Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys<O003753>85 90 95 Val Arg Gly Glu Asn Trp Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Leu Thr Val Ser Ser 115 <210> 140 <211> 118 <212> PRT <213> Mouse <400> 140 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu I 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr 20 25 30 Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met 35 40 45 Gly Leu Ile Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Asp Phe 50 55 60 [ Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Val Arg Gly Glu Asn Trp Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Leu Thr Val Ser Ser 115 <210> 141 <211> 118 <212> PRT <213> Mouse <400> 141 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr 20 25 30 Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met 35 40 45 Gly Leu Ile Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Val Arg Gly Glu Asn Trp Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Leu Thr Val Ser Ser 115 <210> 142 <211> 118 <212> PRT <213> Mouse <400> 142 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr 20 25 30 Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met 35 40 45 Gly Met Ile Tyr Ser Asp Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Arg Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Val Arg Gly Glu Asn Trp Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Leu Thr Val Ser Ser 115 <210> 143 <211> 116 <212> PRT <213> Mouse <400> 143 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr 20 25 30 Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met 35 40 45 Gly Met Ile Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Phe 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asp Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Val Arg Glu Gly Ser Ser Pro Asp Tyr Trp Gly Gln Gly Thr Thr Leu 100 105 110 Thr Val Ser Ser 115 <210> 144 <211> 116 <212> PRT <213> Mouse <400> 144 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr 20 25 30 Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met 35 40 45 Gly Met Ile Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Phe 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Val Arg Ser Arg Leu Leu Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu 100 105 110 Thr Val Ser Ser 115 <210> 145 <211> 118 <212> PRT <213> Mouse <400> 145 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr 20 25 30 Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met 35 40 45 Gly Met Ile Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Val Arg Gly Glu Asn Trp Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Pro Leu Thr Val Ser Ser 115 <210> 146 <211> 118 <212> PRT <213> Mouse <400> 146 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Phe 20 25 30 Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 35 40 45 Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Asn Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ser Thr Tyr Phe Cys 85 90 95 Ala Arg Asp Asp Asp Tyr Asp Gly Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ala 115 <210> 147 <211> 118 <212> PRT <213> Mouse <400> 147 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Phe 20 25 30 Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 35 40 45 Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Ala Ala Thr Tyr Phe Cys 85 90 95 Ala Arg Asp Asp Asp Tyr Asp Gly Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ala 115 <210> 148 <211> 119 <212> PRT <213> Mouse <400> 148 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 35 40 45 Gly Trp Ile Asn Thr Phe Ser Gly Val Ala Thr Tyr Ala Asp Asp Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Ser Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Ala Arg Gly Gly Asn Trp Asp Trp Tyr Phe Asp Val Trp Gly Thr Gly 100 105 110 Thr Thr Val Thr Val Ser Ser 115 <210> 149 <211> 118 <212> PRT <213> Mouse <400> 149 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 35 40 45 Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Lys Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Ser Arg Asp Asp Asp Tyr Asp Gly Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ala 115 <210> 150 <211> 118 <212> PRT <213> Mouse <400> 150 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 35 40 45 Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Ala Arg Asp Asp Asp Tyr Asp Gly Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ala 115 <210> 151 <211> 118 <212> PRT <213> Mouse <400> 151 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 35 40 45 Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Ala Arg Asp Asp Asp Tyr Glu Gly Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ala 115 <210> 152 <211> 119 <212> PRT <213> Mouse <400> 152 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 35 40 45 Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Ala Arg Gly Gly Asn Trp Asp Trp Tyr Phe Asp Val Trp Gly Thr Gly 100 105 110 Thr Thr Val Thr Val Ser Ser 115 <210> 153 <211> 118 <212> PRT <213> Mouse <400> 153 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 35 40 45 Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Ser Arg Asp Asp Asp Tyr Asp Gly Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ala 115 <210> 154 <211> 118 <212> PRT <213> Mouse <400> 154 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 35 40 45 Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe 50 55 60 Lys Gly Arg Phe Ala Ile Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Ala Arg Asp Asp Asp Tyr Asp Gly Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ala 115 <210> 155 <211> 118 <212> PRT <213> Mouse <400> 155 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Leu 35 40 45 Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Asp Asp Gly Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Ala Arg Asp Asp Asp Tyr Asp Gly Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ala 115 <210> 156 <211> 117 <212> PRT <213> Mouse <400> 156 Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 1 5 10 15 Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr 20 25 30 Ala Ile Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45 Gly Ile Ile Trp Thr Thr Gly Gly Thr Asn Tyr Asn Ser Ala Leu Lys 50 55 60 Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu 65 70 75 80 Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Arg Tyr Tyr Cys Ala 85 90 95 Arg Asn Trp Val Asp Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 157 <211> 121 <212> PRT <213> Mouse <400> 157 Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 1 5 10 15 Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Asn 20 25 30 Ala Ile Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45 Gly Val Ile Trp Thr Gly Gly Gly Ile Asn Tyr Asn Ser Ala Leu Lys 50 55 60 Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu 65 70 75 80 Lys Met Asn Ser Leu Glu Thr Asp Asp Thr Ala Arg Tyr Tyr Cys Ala 85 90 95 Arg Trp Asp Tyr Tyr Tyr Gly Ser Arg Trp Tyr Phe Asp Val Trp Gly 100 105 110 Thr Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 158 <211> 117 <212> PRT <213> Mouse <400> 158 Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 1 5 10 15 Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45 Gly Ile Ile Trp Thr Thr Gly Gly Thr Asn Tyr Asn Ser Ala Leu Lys 50 55 60 Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu 65 7,0 75 80 Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Arg Tyr Tyr Cys Ala 85 90 95 Arg Asn Trp Val Asp Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 159 <211> 117 <212> PRT <213> Mouse <400> 159 Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln 1 5 10 15 Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr 20 25 30 Gly Ile His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45 Gly Val Ile Trp Ser Gly Gly Ser Thr Tyr Tyr Asn Ala Ala Phe Ile 50 55 60 Ser Arg Leu Ser Ile Ser Lys Asp Ile Ser Lys Ser Gln Val Phe Phe 65 70 75 80 Lys Met Asn Ser Leu Gln Ala Asp Asp Thr Ala Thr Tyr Tyr Cys Ala 85 90 95 Ser Pro Lys Trp Asp Asp Ala Leu Asp Tyr Trp Gly Gln Gly Ser Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 160 <211> 114 <212> PRT <213> Mouse <400> 160 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Met Arg Pro Gly Ser 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met Asp Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asn Ile Tyr Pro Ser Asp Ser Glu Thr His Tyr Asn Gln Lys Phe 50 55 60 Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Ile Thr Gly Thr Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 100 105 110 Ser Ser <210> 161 <211> 122 <212> PRT <213> Mouse <400> 161 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Trp Met His Trp Met Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Met Ile His Pro Asn Ser Gly Ser Thr Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Arg Gly Tyr Tyr Ser Asn Tyr Gly Asp Ala Met Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 162 <211> 123 <212> PRT <213> Mouse <400> 162 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Trp Met Gln Trp Ile Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asp Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Arg Tyr Tyr Gly Ser Arg Arg Asp Trp Tyr Phe Asp Val 100 105 110 Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 163 <211> 122 <212> PRT <213> Mouse <400> 163 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Met Ile His Pro Asn Ser Gly Asn Thr Asn Tyr Asn Ala Lys Phe 50 55 60 Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Gly Arg Arg Gly Tyr Tyr Ser Asn Tyr Gly Asp Ala Met Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 164 <211> 122 <212> PRT <213> Mouse <400> 164 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Met Ile His Pro Asn Ser Gly Asn Thr Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Lys Ala Ile Leu Thr Val Asp Lys Ser Ser Ser Thr Val Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Gly Arg Arg Gly Tyr Tyr Ser Asn Tyr Gly Asp Ala Met Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 165 <211> 122 <212> PRT <213> Mouse <400> 165 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Met Ile His Pro Asn Ser Gly Ser Thr Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Thr Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Gly Arg Arg Gly Phe Tyr Ser Asn Tyr Gly Asp Ala Met Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 166 <211> 122 <212> PRT <213> Mouse <400> 166 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Met Ile His Pro Asn Ser Gly Ser Thr Asn Tyr Asn Glu Lys Leu 50 55 60 Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Gly Arg Arg Gly Tyr Tyr Ser Asn Tyr Gly Asp Ala Met Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 167 <211> 114 <212> PRT <213> Mouse <400> 167 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Ser 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met Asp Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly His Ile Tyr Pro Ser Asp Ser Glu Thr His Tyr Asn Gln Glu Phe 50 55 60 Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Ile Thr Gly Thr Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 100 105 110 Ser Ser <210> 168 <211> 114 <212> PRT <213> Mouse <400> 168 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Ser 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met Asp Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asn Ile Tyr Pro Ser Asp Ser Glu Thr His Tyr Asn Gln Lys Phe 50 55 60 Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Ile Thr Gly Thr Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 100 105 110 Ser Ser <210> 169 <211> 114 <212> PRT <213> Mouse <400> 169 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Ser 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met Asp Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asn Ile Tyr Pro Ser Asp Ser Glu Thr His Tyr Asn Gln Lys Phe 50 55 60 Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Ile Thr Gly Thr Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 100 105 110 Ser Ser <210> 170 <211> 118 <212> PRT <213> Mouse <400> 170 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Thr 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Val Ile Ala Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Ile Gly Trp Pro Leu Gly His Trp Gly Gln Gly Thr 100 105 110 Thr Leu Thr Val Ser Ser 115 <210> 171 <211> 114 <212> PRT <213> Mouse <400> 171 Gln Val Gln Leu Gln Gln Pro Gly Thr Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ala Ser Tyr 20 25 30 Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asn Ile Asn Pro Ser Asp Gly Asp Thr Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Thr Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 100 105 110 Ser Ser <210> 172 <211> 114 <212> PRT <213> Mouse <400> 172 Gln Val Gln Leu Gln Gln Pro Gly Thr Glu Leu Val Arg Pro Gly Thr 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asn Ile Asp Pro Ser Asn Gly Asp Thr Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Ser Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Leu 100 105 110 Ser Ser <210> 173 <211> 116 <212> PRT <213> Mouse <400> 173 Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Thr Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Trp Ile Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Leu Pro Gly Ser Gly Ser Thr Asn Ser Asn Glu Lys Phe 50 55 6" Lys Gly Lys Ala Thr Phe Thr Ala Asp Pro Ser Ser Asn Thr Val Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Thr Glu Asp Ser Ala Ile Tyr Tyr Cys 85 90 95 Ala Ser Ser Gly Thr Asp Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu 100 105 110 Thr Val Ser Ser[[ID = 46]] [[ID = 47]]115[[ID = 48]] [[ID = 49]]<210> 174[[ID = 50]] [[ID = 51]]<211> 116 <212> PRT <213> Mouse <400> 174 Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Thr Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Trp Leu Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Leu Pro Gly Ser Gly Lys Thr Asn Ser Asn Glu Lys Phe 50 55 60 Lys Gly Lys Ala Thr Phe Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Thr Glu Asp Ser Ala Ile Tyr Tyr Cys 85 90 95 Ala Ser Ser Gly Thr Asp Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu 100 105 110 Thr Val Ser Ser 115 <210> 175 <211> 116 <212> PRT <213> Mouse <400> 175 Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Thr Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Trp Val Glu Trp Ile Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Leu Pro Gly Ser Gly Ser Ser Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Val Asn 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Thr Glu Asp Ser Ala Ile Tyr Tyr Cys 85 90 95 Ala Ser Ser Gly Thr Asp Phe Asp Tyr Trp Gly Gln Gly Thr Thr Val 100 105 110 Thr Val Ser Ser 115 <210> 176 <211> 113 <212> PRT <213> Mouse <400> 176 Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Arg Asp 20 25 30 Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Gln Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Gln Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser 100 105 110 Ser <210> 177 <211> 113 <212> PRT <213> Mouse <400> 177 Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Arg Tyr 20 25 30 Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Gln Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Val Gln Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser 100 105 110 Ser <210> 178 <211> 114 <212> PRT <213> Mouse <400> 178 Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Phe 20 25 30 Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Gln Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Ala Asp Asn Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Arg Gly Gly Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val 100 105 110 Ser Ser <210> 179 <211> 120 <212> PRT <213> Mouse <400> 179 Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr 1 5 10 15 Ser Leu Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Ser 20 25 30 Leu Ile Glu Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Val Ile Asn Pro Gly Ser Gly Gly Thr Asn Tyr Asn Glu Lys Phe 50 55 60​​​​​​​​​​​​​​​​​<210> 180 <211> 118 <212> PRT <213> Mouse <400> 180 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser 20 25 30 Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asp Gly Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Arg Asp Phe Gly Pro Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr 100 105 110 Thr Val Thr Val Ser Ser<o004609>115 <210> 181 <211> 117 <212> PRT <213> Mouse <400> 181 It should be noted that there may be a typo in the original text where "<o004609>" is likely a misspelling and should probably be " ". This has been left as is in the translation as per the instruction to preserve all 7 - digit tags exactly.Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser 20 25 30 Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe 50 55 60 Lys Gly Glu Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 [[ID=I24]]Ala Tyr Gly Ser Arg Gly Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr 100 105 110 Val Thr Val Ser Ser [[ID=I29]] 115 <210> 182 ><211> 118 <212> PRT <213> Mouse <400> 182 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Note: There seems to be an "I24" in the original text which might be a mistake. I've translated it as "Ala Tyr Gly Ser Arg Gly Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr" as normal. And for the "Mouse" translation in ID=38, it's a common translation for "小鼠" in the context of species in biology related texts. Also, the "<210> 182" etc. are likely some kind of identifiers or metadata which are usually left as is in translations of such technical texts.Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser 20 25 30 Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Arg Asp Phe Gly Pro Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 183 <211> 117 <212> PRT <213> Mouse <400> 183 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser 20 25 30 Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Arg Gly Gly Arg Gly Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr 100 105 110 Val Thr Val Ser Ser 115 <210> 184 <211> 117 <212> PRT <213> Mouse <400> 184 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser 20 25 30 Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Tyr Gly Ser Arg Gly Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr 100 105 110 Val Thr Val Ser Ser 115 <210> 185 <211> 118 <212> PRT <213> Mouse <400> 185 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser 20 25 30 Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Glu Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Arg Asp Phe Gly Pro Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 186 <211> 118 <212> PRT <213> Mouse[[ID=2t3]] <400> 186 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser 20 25 30 Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Arg Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Ala Ala Tyr 65 70 75 80 It should be noted that there seems to be a misspelling in the original text where "2t3" should probably be "213". The above translation has been corrected accordingly.Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Arg Asp Phe Gly Pro Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr 100 105 110 Thr Val Ser Val Ser Ser 115 <210> 187 <211> 117 <212> PRT <213> Mouse <400> 187 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser 20 25 30 Trp Met Thr Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe 50 55 60 Glu Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Arg Ala Leu Trp Leu Pro Phe Asp Tyr Trp Gly Gln Gly Thr Thr 100 105 110 Leu Thr Val Ser Ser 115 <210> 188 <211> 117 <212> PRT <213> Mouse <400> 188 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser 20 25 30 Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Arg Asn Asp Tyr Asp Glu Gly Glu Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 189 <211> 117 <212> PRT <213> Mouse <400> 189 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Tyr Ser 20 25 30 Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Ser Gly Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Arg Asn Asp Tyr Asp Glu Gly Glu Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 190 <211> 117 <212> PRT <213> Mouse <400> 190 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Val Phe Ser Ser Ser 20 25 30 Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Tyr Gly Ser Arg Gly Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr 100 105 110 Val Thr Val Ser Ser 115 <210> 191 <211> 121 <212> PRT <213> Mouse <400> 191 Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Ser Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Met Gly Val Ser Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu 35 40 45 Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val 65 70 75 80 Phe Leu Lys Ile Thr Ser Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Arg Ala Asn Gly Tyr Tyr Ala Tyr Phe Asp Val Trp Gly 100 105 110 Thr Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 192 <211> 107 <212> PRT <213> Mouse <400> 192 Asp Phe Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Thr Val Gly 1 5 10 15 Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Met Gln Ser 65 70 75 80 Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 193 <211> 107 <212> PRT <213> Mouse <400> 193 Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Cys Ala Ser Leu Gly 1 5 10 15 Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Tyr Asn Tyr 20 25 30 Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile 35 40 45 Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr 65 70 75 80 Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Arg 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 194 <211> 106 <212> PRT <213> Mouse <400> 194 Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly 1 5 10 15 Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Ile Ser Tyr 20 25 30 Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile 35 40 45 Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr 65 70 75 80 Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Arg Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 195 <211> 106 <212> PRT <213> Mouse <400> 195 Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly 1 5 10 15 Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Asn Tyr 20 25 30 Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile 35 40 45 Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr 65 70 75 80 Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Arg Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 196 <211> 106 <212> PRT <213> Mouse <400> 196 Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly 1 5 10 15 Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Phe 20 25 30 Leu Ile Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile 35 40 45 Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr 65 70 75 80 Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Arg Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 197 <211> 107 <212> PRT <213> Mouse <400> 197 Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly 1 5 10 15 Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr 20 25 30 Leu Arg Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile 35 40 45 Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr 65 70 75 80 Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Phe 85 90 95 Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 198 <211> 106 <212> PRT <213> Mouse <400> 198​​​​​​​​​​​​​​​​​Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr 65 70 75 80 Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Arg Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 199 <211> 107 <212> PRT <213> Mouse <400> 199 Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Pro Ser Leu Gly 1 5 10 15 Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Asn Tyr 20 25 30 Leu Arg Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile 35 40 45 Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Gln Asp Tyr Ala Leu Thr Ile Ser Ser Leu Glu Tyr 65 70 75 80 Glu Asp Met Ala Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Phe 85 90 95 Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 200 <211> 107 <212> PRT <213> Mouse <400> 200 Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val 35 40 45 Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Asn Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His His Tyr Gly Thr Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 201 <211> 107 <212> PRT <213> Mouse <400> 201 Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val 35 40 45 Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Asn Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Gly Thr Tyr Tyr Cys Gln His His Tyr Gly Thr Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 202 <211> 107 <212> PRT <213> Mouse <400> 202 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Glu Arg Val Ser Leu Thr Cys Arg Ala Ser Gln Glu Ile Ser Gly Tyr 20 25 30 Leu Ser Trp Leu Gln Gln Lys Pro Asp Gly Thr Ile Lys Arg Leu Ile 35 40 45 Tyr Ala Ala Ser Thr Leu Asp Ser Gly Val Pro Glu Arg Phe Ser Gly 50 55 60 Ser Trp Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser 65 70 75 80 Glu Asp Phe Ala Asp Tyr Tyr Cys Leu Gln Tyr Ala Ser Tyr Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 203 <211> 107 <212> PRT <213> mice <400> 203 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Glu Arg Val Ser Leu Thr Cys Arg Ala Ser Gln Glu Ile Ser Gly Tyr 20 25 30 Leu Ser Trp Leu Gln Gln Lys Pro Asp Gly Thr Ile Lys Arg Leu Ile 35 40 45 Tyr Ala Ala Ser Thr Leu Asp Ser Gly Val Pro Lys Arg Phe Ser Gly 50 55 60 Ser Arg Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser 65 70 75 80 Glu Asp Phe Ala Asp Tyr Tyr Cys Leu Gln Cys Ala Asn Tyr Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Leu Lys 100 105 <210> 204 <211> 107 <212> PRT <213> Mouse <400> 204 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Gly Lys Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Lys Tyr 20 25 30 Ile Ala Trp Tyr Gln His Lys Pro Gly Lys Gly Pro Arg Leu Leu Ile 35 40 45 His Tyr Thr Ser Thr Leu Gln Pro Gly Ile Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Arg Asp Tyr Ser Phe Ser Ile Arg Asn Leu Glu Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Asn Leu Pro Arg 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 205 <211> 106 <212> PRT <213> Mouse <400> 205 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Gly Lys Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Lys Tyr 20 25 30 Ile Ala Trp Tyr Gln His Lys Pro Gly Lys Gly Pro Arg Leu Leu Ile 35 40 45 His Tyr Thr Ser Thr Leu Gln Pro Gly Ile Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Arg Asp Tyr Ser Phe Ser Ile Ser Asn Leu Glu Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Asn Leu Arg Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 206 <211> 107 <212> PRT <213> Mouse <400> 206 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Gly Lys Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Lys Tyr 20 25 30 Ile Ala Trp Tyr Gln His Lys Pro Gly Lys Gly Pro Arg Leu Leu Ile 35 40 45 His Tyr Thr Ser Thr Leu Gln Pro Gly Ile Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Arg Asp Tyr Ser Phe Ser Ile Ser Asn Leu Glu Pro 65 70 75 80 Glu Asp Ile Val Thr Tyr Tyr Cys Leu Gln Tyr Asp Asn Leu Pro Arg 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 207 <211> 107 <212> PRT <213> Mouse <400> 207 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Gly Lys Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Asn Phe 20 25 30 Leu Ala Trp Tyr Gln His Lys Pro Gly Lys Gly Pro Arg Leu Leu Ile 35 40 45 His Tyr Thr Ser Thr Leu Gln Pro Gly Ile Pro Ser Arg Phe Ser Gly 50 55 60 Gly Gly Ser Gly Arg Asp Tyr Ser Phe Thr Ile Ser Asn Leu Glu Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Asp Leu Pro Arg 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 208 <211> 106 <212> PRT <213> Mouse <400> 208 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Gly Lys Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Asn Tyr 20 25 30 Ile Ala Trp Cys Gln His Lys Pro Gly Lys Gly Pro Arg Leu Leu Ile 35 四十 45 His Tyr Thr Ser Thr Leu Gln Pro Gly Ile Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Arg Asp Tyr Ser Phe Ser Ile Asn Asn Leu Glu Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Asn Leu Tyr Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 209 <211> 106 <212> PRT <213> Mouse <400> 209 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Gly Lys Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Asn Tyr 20 25 30 Ile Ala Trp Tyr Gln His Lys Pro Gly Lys Gly Pro Arg Leu Leu Ile 35 40 45 His Tyr Thr Ser Thr Leu Gln Pro Gly Ile Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Arg Asp Tyr Ser Phe Ser Ile Asn Asn Leu Glu Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Asn Leu Tyr Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 210 <211> 107 <212> PRT <213> Mouse <400> 210 Asp Ile Gln Met Thr Gln Ser Ser Ser Ser Phe Ser Glu Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ile Cys Lys Ala Ser Glu Asp Ile Tyr Asn Arg 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile<00(...)5193>35 40 45 Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Met Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr 65 70 75 80 Glu Asp Val Ala Ser Tyr Tyr Cys Gln Gln Tyr Trp Asn Ile Pro Phe 85 90 95 Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 211 <211> 107 <212> PRT <213> Mouse <400> 211 Asp Ile Gln Met Thr Gln Ser Ser Ser Ser Phe Ser Val Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Ile Phe Asn Arg 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile 35 40 45 Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Lys Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr 65 70 75 80 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Thr Ile Pro Phe 85 90 95 Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 212 <211> 107 <212> PRT <213> Mouse <400> 212 Asp Ile Gln Met Thr Gln Ser Ser Ser Ser Phe Ser Val Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Ile Tyr Asn Arg 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile 35 40 45 Ser Gly Ala Thr Ser Leu Glu Thr Gly Ile Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Lys Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr 65 70 75 80 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Asn Ile Pro Phe 85 90 95 Thr Phe Gly Ser Gly Thr Lys Leu Val Ile Lys 100 105 <210> 213 <211> 107 <212> PRT <213> Mouse <400> 213 Asp Ile Gln Met Thr Gln Ser Ser Ser Ser Phe Ser Val Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Ile Tyr Asn Arg 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile 35 40 45 Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Lys Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr 65 70 75 80 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Gln Asn Thr Pro Phe 85 90 95 Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 214 <211> 107 <212> PRT <213> Mouse <400> 214 Asp Ile Gln Met Thr Gln Ser Ser Ser Ser Phe Ser Val Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Ile Tyr Asn Arg 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile 35 40 45 Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Lys Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr 65 70 75 80 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Asn Ile Pro Phe 85 90 95 Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 215 <211> 107 <212> PRT <213> Mouse <400> 215 Asp Ile Gln Met Thr Gln Ser Ser Ser Ser Phe Ser Val Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Ile Tyr Asn Arg 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile 35 40 45 Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Lys Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr 65 70 75 80 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Ser Thr Pro Arg 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 216 <211> 107 <212> PRT <213> Mouse <400> 216 Asp Ile Gln Met Thr Gln Ser Ser Ser Ser Phe Ser Val Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Ile Tyr Asn Arg 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile 35 40 45 Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Lys Asp Tyr Thr Leu Ser Thr Thr Ser Val Gln Thr 65 70 75 80 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Asn Thr Pro Phe 85 90 95 Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 217 <211> 107 <212> PRT <213> Mouse <400> 217 Asp Ile Gln Met Thr Gln Ser Ser Ser Tyr Leu Ser Val Ser Leu Gly 1 5 10 15 Gly Arg Val Thr Ile Pro Cys Arg Ala Ser Asp His Ile Asn Asn Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile 35 40 45 Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60<able> Ser Gly Ser Gly Lys Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr 65 70 75 80 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Ser Thr Pro Leu 85 90 95 Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 100 105 <210> 218 <211> 107 <212> PRT <213> Mouse <400> 218 Asp Ile Gln Met Thr Gln Ser Ser Ser Tyr Leu Ser Val Ser Leu Gly 1 5 10 15 Gly Arg Val Thr Ile Thr Cys Lys Ala Ser Asp His Ile Asn Asn Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile 35 40 45 Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 It should be noted that there seems to be an error in the tag `<able> ` in the original text, which is likely a misrepresentation. It should probably be ` `. This has been maintained in the translation as best as possible while keeping the original text structure intact.Ser Gly Ser Gly Lys Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr 65 70 75 80 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Ser Ile Pro Leu 85 90 95 Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 100 105 <210> 219 <211> 107 <212> PRT <213> Mouse <400> 219 Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Asn Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Thr Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Leu 85 90 95 Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 100 105 <210> 220 <211> 107 <212> PRT <213> Mouse <400> 220 Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Phe 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile [[ID=用24]]35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly [[ID=用28]]50 55 60 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asp Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 221 <211> 107 <212> PRT <213> Mouse <400> 221 Note: There seems to be a small error in the original text where "用24" and "用28" are present. They should probably be "24" and "28" respectively. The translation has been done as per the correct understanding of the text.Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Phe 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Val Asn Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 222 <211> 107 <212> PRT <213> Mouse <400> 222 Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 35 40 45 Tyr Tyr Ile Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 223 <211> 107 <212> PRT <213> Mouse <400> 223 Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Pro 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 224 <211> 107 <212> PRT <213> Mouse <400> 224 Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 于55 60 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp 85 90 95<? It should be noted that there seems to be an error in the original text where "于55" in line might be incorrect. I've translated it as it is but it might need to be corrected in the original for a more accurate translation.Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 225 <211> 107 <212> PRT <213> Mouse <400> 225 Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asn Ser Ser Leu Pro Ile Asn Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 226 <211> 107 <212> PRT <213> Mouse <400> 226 Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Asn Pro Asp Gly Thr Val Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 227 <211> 107 <212> PRT <213> Mouse <400> 227 Asp Ile Arg Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly 1 5 10 15 Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Phe 20 25 30 Leu Gly Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile 35 40 45 Ser Arg Ala Ser Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr 65 70 75 80 Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 228 <211> 111 <212> PRT <213> mice <400> 228 Asp Ile Val Leu Thr Gln Ser Leu Ala Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Glu Tyr Tyr 20 25 30 Gly Thr Ser Leu Met Gln Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Tyr Ala Ala Ser Asn Val Glu Ser Gly Val Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His 65 70 75 80 Pro Val Glu Glu Asp Asp Ile Ala Val Tyr Phe Cys Gln Gln Ser Arg 85 90 95 Lys Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 229 <211> 111 <212> PRT <213> Mouse <400> 229 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Ile Ser Leu Gly 1 5 10 15 Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser 20 25 30 Ser Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 65 70 75 80 Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp 85 90 95 Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 230 <211> 111 <212> PRT <213> Mouse <400> 230 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Leu Ser Leu Gly 1 5 10 15 Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Ser Ile Ile 20 25 30 Gly Thr Asn Leu Ile Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Tyr His Thr Ser Asn Leu Glu Thr Gly Val Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp 65 70 75 80 Pro Val Glu Glu Asp Asp Val Ala Ile Tyr Tyr Cys Leu Gln Ser Arg 85 90 95 Lys Ile Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 231 <211> 111 <212> PRT <213> Mouse <400> 231 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Met Ser Leu Gly 1 5 10 15 Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Ser Ile Ile 20 25 30 Gly Ala Asn Leu Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Phe His Ala Ser Asn Leu Glu Thr Gly Val Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp 65 70 75 80 Pro Val Glu Glu Asp Asp Val Ala Ile Tyr Tyr Cys Leu Gln Ser Arg 85 90 95 Lys Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 232 <211> 111 <212> PRT <213> mice <400> 232 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Met Ser Leu Gly 1 5 10 15 Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Ser Ile Ile 20 25 30 Gly Thr Asn Leu Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Phe His Ala Ser Asn Leu Glu Thr Gly Val Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp 65 70 75 80 Pro Val Glu Glu Asp Asp Val Ala Ile Tyr Tyr Cys Leu Gln Ser Lys 85 90 95 Lys Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 233 <211> 111 <212> PRT <213> Mouse <400> 233 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Met Ser Leu Gly 1 5 10 15 Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Ser Ile Ile 20 25 30 Gly Thr Asn Leu Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Phe His Ala Ser Asn Leu Glu Thr Gly Val Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp 65 70 75 80 Pro Val Glu Glu Asp Asp Val Ala Ile Tyr Tyr Cys Leu Gln Ser Arg 85 90 95 Lys Ile Pro Tyr Thr Phe Gly Gly Gly Thr Glu Leu Glu Ile Lys 100 105 110 <210> 234 <211> 111 <212> PRT <213> Mouse <400> 234 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Met Ser Leu Gly 1 5 10 15 Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Ser Ile Ile 20 25 30 Gly Thr Asn Leu Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Tyr His Ala Ser Asn Leu Glu Thr Gly Val Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp 65 70 75 80 Pro Val Glu Glu Asp Asp Val Ala Ile Tyr Tyr Cys Leu Gln Ser Arg 85 90 95 Lys Ile Pro Cys Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 235 <211> 111 <212> PRT <213> Mouse <400> 235 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Met Ser Leu Gly 1 5 10 15 Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Ser Ile Ile 20 25 30 Gly Thr Asn Leu Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Tyr His Ala Ser Asn Leu Glu Thr Gly Val Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp 65 70 75 80 Pro Val Glu Glu Asp Asp Val Ala Ile Tyr Tyr Cys Leu Gln Ser Arg 85 90 95 Lys Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 236 <211> 111 <212> PRT <213> Mouse <400> 236 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Phe Leu Gly 1 5 10 15 Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser 20 25 30 Ser Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 65 70 75 80 Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp 85 90 95 Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 237 <211> 111 <212> PRT <213> Mouse <400> 237 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Ser Ile Ile 20 25 30 Gly Ala Asn Leu Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Phe His Ala Ser Asn Leu Glu Thr Gly Val Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp 65 70 75 80 Pro Val Glu Glu Asp Asp Ile Ala Ile Tyr Phe Cys Leu Gln Ser Arg 85 90 95 Lys Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 238 <211> 111 <212> PRT <213> Mouse <400> 238 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu ...

Claims

1. An antibody or antigen-binding fragment thereof that binds to the SARS-CoV-2S protein, characterized in that... Includes one of the following combinations: a) HCDR1 with amino acid sequence SEQ ID NO:382, HCDR2 with amino acid sequence SEQ ID NO:383, HCDR3 with amino acid sequence SEQ ID NO:446, LCDR1 with amino acid sequence SEQ ID NO:608, LCDR2 with amino acid sequence SEQ ID NO:609, and LCDR3 with amino acid sequence SEQ ID NO:610; b) HCDR1 with amino acid sequence SEQ ID NO:519, HCDR2 with amino acid sequence SEQ ID NO:522, HCDR3 with amino acid sequence SEQ ID NO:523, LCDR1 with amino acid sequence SEQ ID NO:622, LCDR2 with amino acid sequence SEQ ID NO:726, and LCDR3 with amino acid sequence SEQ ID NO:727; c) HCDR1 with amino acid sequence SEQ ID NO:391, HCDR2 with amino acid sequence SEQ ID NO:386, HCDR3 with amino acid sequence SEQ ID NO:581, LCDR1 with amino acid sequence SEQ ID NO:608, LCDR2 with amino acid sequence SEQ ID NO:609, and LCDR3 with amino acid sequence SEQ ID NO:

766. The amino acid sequence of the SARS-CoV-2S protein is shown in SEQ ID NO:

1.

2. The antibody or antigen-binding fragment thereof according to claim 1, wherein the amino acid sequence of HCDR1 is SEQ ID NO:382, the amino acid sequence of HCDR2 is SEQ ID NO:383, the amino acid sequence of HCDR3 is SEQ ID NO:446, the amino acid sequence of LCDR1 is SEQ ID NO:608, the amino acid sequence of LCDR2 is SEQ ID NO:609, and the amino acid sequence of LCDR3 is SEQ ID NO:

610.

3. The antibody or antigen-binding fragment thereof according to claim 1, wherein the amino acid sequence of HCDR1 is SEQ ID NO:519, the amino acid sequence of HCDR2 is SEQ ID NO:522, the amino acid sequence of HCDR3 is SEQ ID NO:523, the amino acid sequence of LCDR1 is SEQ ID NO:622, the amino acid sequence of LCDR2 is SEQ ID NO:726, and the amino acid sequence of LCDR3 is SEQ ID NO:

727.

4. The antibody or antigen-binding fragment thereof according to claim 1, wherein the amino acid sequence of HCDR1 is SEQ ID NO:391, the amino acid sequence of HCDR2 is SEQ ID NO:386, the amino acid sequence of HCDR3 is SEQ ID NO:581, the amino acid sequence of LCDR1 is SEQ ID NO:608, the amino acid sequence of LCDR2 is SEQ ID NO:609, and the amino acid sequence of LCDR3 is SEQ ID NO:

766.

5. An antibody or antigen-binding fragment thereof that binds to the SARS-CoV-2S protein, characterized in that... Includes one of the following combinations: a) A VH with the amino acid sequence SEQ ID NO:31, and a VL with the amino acid sequence SEQ ID NO:297; b) A VH with the amino acid sequence SEQ ID NO:161, and a VL with the amino acid sequence SEQ ID NO:366; c) A VH with the amino acid sequence SEQ ID NO:100, and a VL with the amino acid sequence SEQ ID NO:301; The amino acid sequence of the SARS-CoV-2S protein is shown in SEQ ID NO:

1.

6. The antibody or antigen-binding fragment thereof according to claim 5, wherein the amino acid sequence of VH is SEQ ID NO:31 and the amino acid sequence of VL is SEQ ID NO:

297.

7. The antibody or antigen-binding fragment thereof according to claim 5, wherein the amino acid sequence of VH is SEQ ID NO:161 and the amino acid sequence of VL is SEQ ID NO:

366.

8. The antibody or antigen-binding fragment thereof according to claim 5, wherein the amino acid sequence of VH is SEQ ID NO:100 and the amino acid sequence of VL is SEQ ID NO:

301.

9. An antibody or antigen-binding fragment thereof that binds to the SARS-CoV-2S protein, characterized in that... Includes one of the following combinations: a) A heavy chain containing the amino acid sequence SEQ ID NO:31, and a light chain containing the amino acid sequence SEQ ID NO:297; b) A heavy chain comprising the amino acid sequence SEQ ID NO:161, and a light chain comprising the amino acid sequence SEQ ID NO:

366. c) A heavy chain comprising the amino acid sequence SEQ ID NO:100, and a light chain comprising the amino acid sequence SEQ ID NO:301; The amino acid sequence of the SARS-CoV-2S protein is shown in SEQ ID NO:

1.

10. The antibody or antigen-binding fragment thereof according to claim 9, wherein the heavy chain comprises the amino acid sequence SEQ ID NO:31, and the light chain comprises the amino acid sequence SEQ ID NO:

297.

11. The antibody or antigen-binding fragment thereof according to claim 9, wherein the heavy chain comprises the amino acid sequence SEQ ID NO:161, and the light chain comprises the amino acid sequence SEQ ID NO:

366.

12. The antibody or antigen-binding fragment thereof according to claim 9, wherein the heavy chain comprises the amino acid sequence SEQ ID NO:100, and the light chain comprises the amino acid sequence SEQ ID NO:

301.

13. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof as described in any one of claims 1-12.

14. A kit comprising the antibody or antigen-binding fragment thereof as described in any one of claims 1-12 or the pharmaceutical composition as described in claim 13.

15. The use of the antibody or antigen-binding fragment thereof of any one of claims 1-12 or the pharmaceutical composition of claim 13 in the preparation of a medicament for reducing, delaying or otherwise inhibiting the growth and / or replication of SARS-CoV-2 in an individual.

Images